









Supplementary Note 1. NHLBI TOPMed program study participants 
 
Atherosclerosis Risk in Communities study (ARIC, 7,991) 
TOPMed dbGaP accession#: phs001211, Parent dbGaP accession#: phs000280 
ARIC is a large population-based prospective longitudinal cohort study (began 1987) from four 
U.S. communities: Forsyth County, NC; Jackson, MS; the northwest suburbs of Minneapolis, MN; and 
Washington County, MD. ARIC was designed to investigate the etiology and natural history of 
atherosclerosis, its consequences, and related medical care by race, gender, location, and time as 
previously described.1 A total of 15,792 participants (55% female and 27% African American) aged 
45-64 years were recruited between 1987 and 1989 and received extensive examination, including 
medical, social and demographic date. The baseline visit was conducted between 1987 and1989, the 
second visit in 1990-1992, the third visit in 1993-1995, the fourth visit in 1996-1998, the fifth visit in 
2011-2013, the sixth visit in 2016-2017, and the seventh visit in 2018-2019. Follow-up is also 
conducted semi-annually since 2012 by telephone to maintain contact with participants and to assess 
the health status of the cohort.  
The Atherosclerosis Risk in Communities study has been funded in whole or in part with 
Federal funds from the National Heart, Lung, and Blood Institute, National Institutes of Health, 
Department of Health and Human Services (contract numbers HHSN268201700001I, 
HHSN268201700002I, HHSN268201700003I, HHSN268201700004I and HHSN268201700005I). 
The authors thank the staff and participants of the ARIC study for their important contributions. 
Whole genome sequencing (WGS) for the Trans-Omics in Precision Medicine (TOPMed) 
program was supported by the National Heart, Lung and Blood Institute (NHLBI). WGS for “NHLBI 
TOPMed: Atherosclerosis Risk in Communities (ARIC)” (phs001211) was performed at the Baylor 
College of Medicine Human Genome Sequencing Center (HHSN268201500015C and 
3U54HG003273-12S2) and the Broad Institute for MIT and Harvard (3R01HL092577-06S1). 
Centralized read mapping and genotype calling, along with variant quality metrics and filtering were 
provided by the TOPMed Informatics Research Center (3R01HL-117626-02S1). Phenotype 
harmonization, data management, sample-identity QC, and general study coordination, were 
provided by the TOPMed Data Coordinating Center (3R01HL-120393-02S1). We gratefully 
acknowledge the studies and participants who provided biological samples and data for TOPMed.  
The Genome Sequencing Program (GSP) was funded by the National Human Genome 
Research Institute (NHGRI), the National Heart, Lung, and Blood Institute (NHLBI), and the National 
Eye Institute (NEI). The GSP Coordinating Center (U24 HG008956) contributed to cross-program 
scientific initiatives and provided logistical and general study coordination. The Centers for Common 
Disease Genomics (CCDG) program was supported by NHGRI and NHLBI, and whole genome 
sequencing was performed at the Baylor College of Medicine Human Genome Sequencing Center 
(UM1 HG008898 and R01HL059367). 
 
Old Order Amish (Amish, 1,083) 
TOPMed dbGaP accession#: phs000956, Parent dbGaP accession#: phs000391 
The Amish Complex Disease Research Program includes a set of large community-based 
studies focused largely on cardiometabolic health carried out in the Old Order Amish (OOA) 
community of Lancaster, Pennsylvania.2 The OOA population of Lancaster County, PA immigrated to 
the Colonies from Western Europe in the early 1700's. There are now over 30,000 OOA individuals in 
the Lancaster area, nearly all of whom can trace their ancestry back 12-14 generations to 
approximately 700 founders. Investigators at the University of Maryland School of Medicine have 
been studying the genetic determinants of cardiometabolic health in this population since 1993. To 
date, over 7,000 Amish adults have participated in one or more of our studies.  
The Amish studies upon which these data are based were supported by NIH grants R01 
AG18728, U01 HL072515, R01 HL088119, R01 HL121007, and P30 DK072488. WGS for “NHLBI 
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TOPMed: Genetics of Cardiometabolic Health in the Amish” (phs000956) was performed at the Broad 
Institute of MIT and Harvard (3R01HL121007-01S1). 
 
Mt Sinai BioMe Biobank (BioMe, 9,857) 
TOPMed dbGaP accession#: phs001644, Parent dbGaP accession#: phs000925 
The Mount Sinai Institute for Personalized Medicine BioMe Biobank is a consented, EMR-
linked medical care setting biorepository of the Mount Sinai Medical Center drawing from a population 
of over 70,000 inpatients and 800,000 outpatient visits annually.3 The Mount Sinai Medical Center 
services diverse local communitiies of upper Manhattan, including Central Harlem (86% African 
American), East Harlem (88% Hispanic Latino), and Upper East Side (88% Caucasian/white) with 
broad health disparities. Biobank operations are fully integrated in clinical care processes, including 
direct recruitment from clinical sites waiting areas and phlebotomy stations by dedicated Biobank 
recruiters independent of clinical care providers, prior to or following a clinician standard of care visit. 
Recruitment currently occurs at a broad spectrum of over 30 clinical care sites. 
The Mount Sinai BioMe Biobank has been supported by The Andrea and Charles Bronfman 
Philanthropies and in part by Federal funds from the NHLBI and NHGRI (U01HG00638001; 
U01HG007417; X01HL134588). WGS for “NHLBI TOPMed: Mount Sinai BioMe Biobank” 
(phs001644) was performed at the Baylor College of Medicine Human Genome Sequencing Center 
(HHSN268201600033I). We thank all participants in the Mount Sinai Biobank. We also thank all our 
recruiters who have assisted and continue to assist in data collection and management and are 
grateful for the computational resources and staff expertise provided by Scientific Computing at the 
Icahn School of Medicine at Mount Sinai. 
 
Coronary Artery Risk Development in Young Adults (CARDIA, 3,054) 
TOPMed dbGaP accession#: phs001612, Parent dbGaP accession#: phs000285 
The Coronary Artery Risk Development in Young Adults Study (CARDIA) is a study examining 
the etiology and natural history of cardiovascular disease beginning in young adulthood.4 In 1985-
1986, a cohort of 5115 healthy black and white men and women aged 18-30 years were selected to 
have approximately the same number of people in subgroups of age (18-24 and 25-30), sex, race, 
and education (high school or less and more than high school) within each of four US Field Centers. 
These same participants were asked to participate in follow-up examinations during 1987-1988 (Year 
2), 1990-1991 (Year 5), 1992-1993 (Year 7), 1995-1996 (Year 10), 2000-2001 (Year 15), 2005-2006 
(Year 20), 2010-2011 (Year 25); and 2015-2016 (Year 30). A majority of the group has been 
examined at each of the follow-up examinations (91%, 86%, 81%, 79%, 74%, 72%, 72%, and 71%, 
respectively).  In addition to the follow-up examinations, participants are contacted regularly for the 
ascertainment of information on out-patient procedures and hospitalizations experienced between 
contacts. 
The Coronary Artery Risk Development in Young Adults Study (CARDIA) is conducted and 
supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with the 
University of Alabama at Birmingham (HHSN268201800005I & HHSN268201800007I), Northwestern 
University (HHSN268201800003I), University of Minnesota (HHSN268201800006I), and Kaiser 
Foundation Research Institute (HHSN268201800004I). CARDIA was also partially supported by the 
Intramural Research Program of the National Institute on Aging (NIA) and an intra‐agency agreement 
between NIA and NHLBI (AG0005). WGS for “NHLBI TOPMed: Coronary Artery Risk Development in 
Young Adults” (phs001612) was performed at the Baylor College of Medicine Human Genome 
Sequencing Center (HHSN268201600033I). 
 
Cleveland Family Study (CFS, 577) 
TOPMed dbGaP accession#: phs000954, Parent dbGaP accession#: phs000284 
The Cleveland Family Study (CFS) is the largest family-based study of sleep apnea, 
comprising of 2,284 individuals (46% African American) from 361 families studied up to 4 occasions 
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over 16 years, 1990-2006.5, 6, 7, 8 Index probands (n=275) were recruited from 3 area hospital sleep 
labs if they had a confirmed diagnosis of sleep apnea and at least 2 first-degree relatives available to 
be studied. In the first 5 years of the study, neighborhood control probands (n=87) with at least 2 
living relatives available for study were selected at random from a list provided by the index family 
and also studied. All available first-degree relatives and spouses of the case and control probands 
also were recruited. Second-degree relatives, including half-sibs, aunts, uncles and grandparents, 
were also included if they lived near the first-degree relatives (cases or controls), or if the family had 
been found to have two or more relatives with sleep apnea. Blood was sampled and DNA isolated for 
participants seen in the last two exam cycles (n=1,447). 
CFS is supported by grants from the NHLBI (HL046389, HL113338, and 1R35HL135818). 
WGS for “NHLBI TOPMed: Cleveland Family Study - WGS Collaboration” (phs000954) was 
performed at the University of Washington Northwest Genomics Center (3R01HL098433-05S1 and 
HHSN268201600032I). 
 
Cardiovascular Health Study (CHS, 2,773) 
TOPMed dbGaP accession#: phs001368, Parent dbGaP accession#: phs000287 
The Cardiovascular Health Study (CHS) originated in 1988 and is a study of risk factors for 
development and progression of coronary heart disease and stroke in people aged 65 years and 
older.9, 10, 11 The 5,888 study participants were recruited from four U.S. communities and have 
undergone extensive clinic examinations for evaluation of markers of subclinical cardiovascular 
disease. The original cohort totaled 5,201 participants. A new cohort was recruited in 1992. The 687 
participants in the new cohort are predominately African-American and were recruited at three of the 
four field centers. Starting in 1989, and continuing through 1999, participants underwent annual 
extensive clinical examinations. Measurements included traditional risk factors such as blood 
pressure and lipids as well as measures of subclinical disease, including echocardiography of the 
heart, carotid ultrasound, and cranial magnetic-resonance imaging (MRI). At six-month intervals 
between clinic visits, and once clinic visits ended, participants were contacted by phone to ascertain 
hospitalizations and health status. The main outcomes are coronary heart disease (CHD), angina, 
heart failure (HF), stroke, transient ischemic attack (TIA), claudication, and mortality. Participants 
continue to be contacted by phone every 6 months. 
This CHS research was supported by NHLBI contracts HHSN268201200036C, 
HHSN268200800007C, HHSN268201800001C, N01HC55222, N01HC85079, N01HC85080, 
N01HC85081, N01HC85082, N01HC85083, N01HC85086; and NHLBI grants U01HL080295, 
R01HL087652, R01HL105756, R01HL103612, R01HL120393, R01HL130114, and R01 HL059367, 
with additional contribution from the National Institute of Neurological Disorders and Stroke (NINDS). 
Additional support was provided through R01AG023629 from the National Institute on Aging (NIA). A 
full list of principal CHS investigators and institutions can be found at CHS-NHLBI.org. WGS for 
“NHLBI TOPMed: Cardiovascular Health Study” (phs001368) was performed at the Baylor College of 
Medicine Human Genome Sequencing Center (3U54HG003273-12S2, HHSN268201500015C, and 
HHSN268201600033I). The content is solely the responsibility of the authors and does not 
necessarily represent the official views of the National Institutes of Health. 
 
Diabetes Heart Study (DHS, 365) 
TOPMed dbGaP accession#: phs001412, Parent dbGaP accession#: phs001012 
The Diabetes Heart Study (DHS) is a family-based study enriched for type 2 diabetes (T2D).12 
The cohort included 1443 European American and African American participants from 564 families 
with multiple cases of type 2 diabetes. The cohort was recruited between 1998 and 2006. Participants 
were extensively phenotyped for measures of subclinical CVD and other known CVD risk factors. 
Primary outcomes were quantified burden of vascular calcified plaque in the coronary artery, carotid 
artery, and abdominal aorta all determined from non-contrast computed tomography scans. 
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This work was supported by R01 HL92301, R01 HL67348, R01 NS058700, R01 AR48797, 
R01 DK071891, R01 AG058921, the General Clinical Research Center of the Wake Forest University 
School of Medicine (M01 RR07122, F32 HL085989), the American Diabetes Association, and a pilot 
grant from the Claude Pepper Older Americans Independence Center of Wake Forest University 
Health Sciences (P60 AG10484). WGS for “NHLBI TOPMed: Diabetes Heart Study” (phs001412) 
was performed at the Broad Institute of MIT and Harvard (HHSN268201500014C). 
 
Framingham Heart Study (FHS, 3,990) 
TOPMed dbGaP accession#: phs000974, Parent dbGaP accession#: phs000007 
The Framingham Heart Study (FHS) is a prospective cohort study of 3 generations of subjects 
who have been followed up to 65 years to evaluate risk factors for cardiovascular disease.13, 14, 15, 16 
Its large sample of ~15,000 men and women who have been extensively phenotyped with repeated 
examinations make it ideal for the study of genetic associations with cardiovascular disease risk 
factors and outcomes. DNA samples have been collected and immortalized since the mid-1990s and 
are available on ~8000 study participants in 1037 families. These samples have been used for 
collection of GWAS array data and exome chip data in nearly all with DNA samples, and for targeted 
sequencing, deep exome sequencing and light coverage whole genome sequencing in limited 
numbers. Additionally, mRNA and miRNA expression data, DNA methylation data, metabolomics and 
other 'omics data are available on a sizable portion of study participants. This project will focus on 
deep whole genome sequencing (mean 30X coverage) in ~4100 subjects and imputed to all with 
GWAS array data to more fully understand the genetic contributions to cardiovascular, lung, blood 
and sleep disorders. 
FHS acknowledges the support of contracts NO1-HC-25195 and HHSN268201500001I from 
the National Heart, Lung and Blood Institute and grant supplement R01 HL092577-06S1 for this 
research. WGS for “NHLBI TOPMed: Whole Genome Sequencing and Related Phenotypes in the 
Framingham Heart Study” (phs000974) was performed at the Broad Institute of MIT and Harvard 
(HHSN268201500014C, 3R01HL092577-06S1, and 3U54HG003067-12S2). We also acknowledge 
the dedication of the FHS study participants without whom this research would not be possible. 
 
Genetic Epidemiology Network of Arteriopathy (GENOA, 1,044) 
TOPMed dbGaP accession#: phs001345, Parent dbGaP accession#: phs001238 
The Genetic Epidemiology Network of Arteriopathy (GENOA) is one of four networks in the 
NHLBI Family-Blood Pressure Program (FBPP).17 GENOA's long-term objective is to elucidate the 
genetics of target organ complications of hypertension, including both atherosclerotic and 
arteriolosclerotic complications involving the heart, brain, kidneys, and peripheral arteries.18 The 
longitudinal GENOA Study recruited European-American and African-American sibships with at least 
2 individuals with clinically diagnosed essential hypertension before age 60 years. All other members 
of the sibship were invited to participate regardless of their hypertension status. Participants were 
diagnosed with hypertension if they had either 1) a previous clinical diagnosis of hypertension by a 
physician with current anti-hypertensive treatment, or 2) an average systolic blood pressure ≥ 140 
mm Hg or diastolic blood pressure ≥ 90 mm Hg based on the second and third readings at the time of 
their clinic visit. Only participants of the African-American Cohort were sequenced through TOPMed. 
Support for GENOA was provided by the National Heart, Lung and Blood Institute (HL054457, 
HL054464, HL054481, and HL087660) of the National Institutes of Health. WGS for “NHLBI 
TOPMed: Genetic Epidemiology Network of Arteriopathy” (phs001345) was performed at the Broad 
Institute of MIT and Harvard (HHSN268201500014C) and the University of Washington Northwest 
Genomics Center (3R01HL055673-18S1). 
 
Genetics of Lipid-Lowering Drugs and Diet Network (GOLDN, 924) 
TOPMed dbGaP accession#: phs001359, Parent dbGaP accession#: phs000741 
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The Genetics of Lipid-Lowering Drugs and Diet Network (GOLDN) study was initiated to 
assess how genetic factors interact with environmental (diet and drug) interventions to influence 
blood levels of triglycerides and other atherogenic lipid species and inflammation markers (registered 
at clinicaltrials.gov, number NCT00083369).19 The study recruited Caucasian participants primarily 
from three-generational pedigrees from two NHLBI Family Heart Study (FHS) field centers 
(Minneapolis, MN and Salt Lake City, UT).20 Only families with at least two siblings were recruited and 
only participants who did not take lipid-lowering agents (pharmaceuticals or nutraceuticals) for at least 
4 weeks prior to the initial visit were included. The diet intervention followed the protocol of Patsch et 
al.21 The whipping cream (83% fat) meal had 700 Calories/m2 body surface area (2.93 mJ/m2 body 
surface area): 3% of calories were derived from protein (instant nonfat dry milk) and 14% from 
carbohydrate (sugar). The ratio of polyunsaturated to saturated fat was 0.06 and the cholesterol 
content of the average meal was 240 mg. The mixture was blended with ice and flavorings. Blood 
samples were drawn immediately before (fasting) and at 3.5 and 6 hours after consuming the high-fat 
meal. The diet intervention was administered at baseline as well as after a 3-week treatment with 160 
mg micronized fenofibrate. Participants were given the option to complete one or both (diet and drug) 
interventions. Of all participants, 1079 had phenotypic data and provided appropriate consent, and 
underwent whole genome sequencing through the TOPMed program. 
GOLDN biospecimens, baseline phenotype data, and intervention phenotype data were 
collected with funding from National Heart, Lung and Blood Institute (NHLBI) grant U01 HL072524. 
WGS for “NHLBI TOPMed: Genetics of Lipid Lowering Drugs and Diet Network” (phs001359) was 
performed at the University of Washington Northwest Genomics Center (3R01HL104135-04S1 and 
R01 HL104135). 
 
Genetic Epidemiology Network of Salt Sensitivity (GenSalt, 1,770) 
TOPMed dbGaP accession#: phs001217, Parent dbGaP accession#: phs000784 
The Genetic Epidemiology Network of Salt-Sensitivity (GenSalt) study, using a family feeding-
study design, aims to identify genes which interact with dietary sodium and potassium intake to 
influence blood pressure in Han Chinese participants from rural north China.22 The dietary 
intervention included a 7-day low-sodium feeding (51.3 mmol/day), a 7-day high-sodium feeding 
(307.8 mmol/day) and a 7-day high-sodium feeding with an oral potassium supplementation (60 
mmol/day). Microsatellite markers for genome-wide linkage scan and single nucleotide polymorphism 
(SNP) markers in candidate genes will be genotyped. Overall, 3153 participants from 658 families 
were recruited for GenSalt. Whole genome sequencing has been conducted for 1,860 participants as 
a part of TOPMed. 
GenSalt was supported by research grants (U01HL072507, R01HL087263, and 
R01HL090682) from the National Heart, Lung and Blood Institute, National Institutes of Health, 
Bethesda, MD. WGS for “NHLBI TOPMed: Genetic Epidemiology Network of Salt Sensitivity” 
(phs001217) was performed at the Baylor College of Medicine Human Genome Sequencing Center 
(HHSN268201500015C). 
 
Genetic Studies of Atherosclerosis Risk (GeneSTAR, 1,755) 
TOPMed dbGaP accession#: phs001218, Parent dbGaP accession#: phs000375 
GeneSTAR began in 1982 as the Johns Hopkins Sibling and Family Heart Study, a 
prospective longitudinal family-based study conducted originally in healthy adult siblings of people 
with documented early onset coronary disease under 60 years of age.23, 24 Commencing in 2003, the 
siblings, their offspring, and the coparent of the offspring participated in a 2 week trial of aspirin 81 
mg/day with pre and post ex vivo platelet function assessed using multiple agonists in whole blood 
and platelet rich plasma. Extensive additional cardiovascular testing and risk assessment was done 
at baseline and serially. Follow-up was carried out to determine incident cardiovascular disease, 
stroke, peripheral arterial disease, diabetes, cancer, and related comorbidities, from 5 to 30 years 
after study entry. The goal of several additional phenotyping and interventional substudies has been 
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to discover and amplify understanding of the mechanisms of atherogenic vascular diseases and 
attendant comorbidities. 
GeneSTAR was supported by grants from the National Institutes of Health/National Heart, 
Lung, and Blood Institute (U01 HL72518, HL087698, HL49762, HL58625, HL071025, HL112064), the 
National Institutes of Health/National Institute of Nursing Research (NR0224103), and by a grant from 
the National Institutes of Health/National Center for Research Resources (M01-RR000052) to the 
Johns Hopkins General Clinical Research Center. WGS for “NHLBI TOPMed: Genetic Studies of 
Atherosclerosis Risk” (phs001218) was performed at the Broad Institute of MIT and Harvard 
(HHSN268201500014C), the Macrogen Corp. (3R01HL112064-04S1), and Illumina (R01HL112064). 
 
Hispanic Community Health Study - Study of Latinos (HCHS/SOL, 7,391) 
TOPMed dbGaP accession#: phs001395, Parent dbGaP accession#: phs000810 
The Hispanic Community Health Study / Study of Latinos (HCHS/SOL) is a multi-center 
epidemiologic study in Hispanic/Latino populations to determine the role of acculturation in the 
prevalence and development of disease, and to identify risk factors playing a protective or harmful 
role in Hispanics/Latinos.25 The goals of the HCHS/SOL include studying the prevalence and 
development of disease in Hispanics/Latinos, including the role of acculturation, and identifying 
disease risk factors that play protective or harmful roles in Hispanics/Latinos. A total of 16,415 
persons of Cuban, Dominican, Mexican, Puerto Rican, Central American, and South American 
backgrounds were recruited through four Field Centers affiliated with San Diego State University, 
Northwestern University in Chicago, Albert Einstein College of Medicine in the Bronx area of New 
York, and the University of Miami. Seven additional academic centers serve as scientific and logistical 
support centers. Study participants aged 18-74 years took part in an extensive clinic exam and 
assessments to ascertain socio-demographic, cultural, environmental and biomedical characteristics. 
Annual follow-up interviews are conducted to determine a range of health outcomes. 
The Hispanic Community Health Study/Study of Latinos was carried out as a collaborative 
study supported by contracts from the National Heart, Lung, and Blood Institute (NHLBI) to the 
University of North Carolina (N01-HC65233), University of Miami (N01-HC65234), Albert Einstein 
College of Medicine (N01-HC65235), Northwestern University (N01-HC65236), and San Diego State 
University (N01-HC65237). The following Institutes/Centers/Offices contribute to the HCHS/SOL 
through a transfer of funds to the NHLBI: National Center on Minority Health and Health Disparities, 
the National Institute of Deafness and Other Communications Disorders, the National Institute of 
Dental and Craniofacial Research, the National Institute of Diabetes and Digestive and Kidney 
Diseases, the National Institute of Neurological Disorders and Stroke, and the Office of Dietary 
Supplements. WGS for “NHLBI TOPMed: Hispanic Community Health Study - Study of Latinos” 
(phs001395) was performed at the Baylor College of Medicine Human Genome Sequencing Center 
(HHSN268201600033I). 
 
Hypertension Genetic Epidemiology Network and Genetic Epidemiology Network of Arteriopathy 
(HyperGEN, 1,853) 
TOPMed dbGaP accession#: phs001293, Parent dbGaP accession#: phs001293 
The Hypertension Genetic Epidemiology Network Study (HyperGEN) - Genetics of Left 
Ventricular (LV) Hypertrophy is a familial study aimed to understand genetic risk factors for LV 
hypertrophy by conducting genetic studies of continuous traits from echocardiography exams.26 The 
originating HyperGEN study aimed to understand genetic risk factors for hypertension.27 HyperGEN 
recruited 470 multiply-affected population-based hypertensive AA sibships (N=1224 siblings) from 
1996-1999. HyperGEN probands were ascertained by early onset hypertension (i.e., before 60 
years); to participate, they had to have at least one hypertensive sibling who was also willing to 
participate. Data from detailed clinical exams as well as genotyping data for linkage studies, 
candidate gene studies and GWAS have been collected and is shared between HyperGEN and the 
ancillary HyperGEN - Genetics of LV Hypertrophy study. 
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The HyperGEN Study is part of the National Heart, Lung, and Blood Institute (NHLBI) Family 
Blood Pressure Program; collection of the data represented here was supported by grants U01 
HL054472 (MN Lab), U01 HL054473 (DCC), U01 HL054495 (AL FC), and U01 HL054509 (NC FC). 
The HyperGEN: Genetics of Left Ventricular Hypertrophy Study was supported by NHLBI grant R01 
HL055673 with whole-genome sequencing made possible by supplement -18S1. WGS for “NHLBI 
TOPMed: Hypertension Genetic Epidemiology Network” (phs001293) was performed at the University 
of Washington Northwest Genomics Center (3R01HL055673-18S1). 
 
Jackson Heart Study (JHS, 2,846) 
TOPMed dbGaP accession#: phs000964, Parent dbGaP accession#: phs000286 
The purpose of the Jackson Heart Study (JHS) is to explore the reasons for heightened 
cardiovascular disease prevalence among African Americans and to uncover new approaches to 
reduce it. The JHS is a large, community-based, observational study whose 5,306 participants were 
recruited from among the non-institutionalized African-American adults from urban and rural areas of 
the three counties (Hinds, Madison, and Rankin) that make up the Jackson, MS, metropolitan 
statistical area (MSA).28, 29, 30 The JHS design included participants from the Jackson ARIC study who 
had originally been recruited through random selection from a drivers' license registry. New JHS 
participants were chosen randomly from the Accudata America commercial listing, which provides 
householder name, address, zip code, phone number (if available), age group in decades, and family 
components. In addition, a family component was included in the JHS. The sampling frame for the 
family study was a participant in any one of the ARlC, random, or volunteer samples whose family 
size met eligibility requirements. Recruitment was limited to persons 35-84 years old except in the 
family cohort, where those 21 years old and above were eligible. 
The Jackson Heart Study (JHS) is supported and conducted in collaboration with Jackson 
State University (HHSN268201800013I), Tougaloo College (HHSN268201800014I), the Mississippi 
State Department of Health (HHSN268201800015I) and the University of Mississippi Medical Center 
(HHSN268201800010I, HHSN268201800011I and HHSN268201800012I) contracts from the 
National Heart, Lung, and Blood Institute (NHLBI) and the National Institute on Minority Health and 
Health Disparities (NIMHD). WGS for “NHLBI TOPMed: The Jackson Heart Study” (phs000964) was 
performed at the University of Washington Northwest Genomics Center (HHSN268201100037C). The 
authors also wish to thank the staffs and participants of the JHS. The authors also wish to thank the 
staffs and participants of the JHS. 
 
Multi-Ethnic Study of Atherosclerosis (MESA, 5,283) 
TOPMed dbGaP accession#: phs001416, Parent dbGaP accession#: phs000209 
The Multi-Ethnic Study of Atherosclerosis (MESA) is a study of the characteristics of 
subclinical cardiovascular disease (disease detected non-invasively before it has produced clinical 
signs and symptoms) and the risk factors that predict progression to clinically overt cardiovascular 
disease or progression of the subclinical disease.31 MESA researchers study a diverse, population-
based sample of 6,814 asymptomatic men and women aged 45-84. Thirty-eight percent of the 
recruited participants are white, 28 percent African-American, 22 percent Hispanic, and 12 percent 
Asian, predominantly of Chinese descent. Participants were recruited from six field centers across the 
United States: Wake Forest University, Columbia University, Johns Hopkins University, University of 
Minnesota, Northwestern University and University of California - Los Angeles. Each participant 
received an extensive exam and determination of coronary calcification, ventricular mass and 
function, flow-mediated endothelial vasodilation, carotid intimal-medial wall thickness and presence of 
echogenic lucencies in the carotid artery, lower extremity vascular insufficiency, arterial wave forms, 
electrocardiographic (ECG) measures, standard coronary risk factors, sociodemographic factors, 
lifestyle factors, and psychosocial factors. Selected repetition of subclinical disease measures and 
risk factors at follow-up visits allows study of the progression of disease. Blood samples have been 
assayed for putative biochemical risk factors and stored for case-control studies. DNA has been 
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extracted and lymphocytes cryopreserved (for possible immortalization) for study of candidate genes 
and possibly, genome-wide scanning, expression, and other genetic techniques. Participants are 
being followed for identification and characterization of cardiovascular disease events, including acute 
myocardial infarction and other forms of coronary heart disease (CHD), stroke, and congestive heart 
failure; for cardiovascular disease interventions; and for mortality. 
Whole genome sequencing (WGS) for the Trans-Omics in Precision Medicine (TOPMed) 
program was supported by the National Heart, Lung and Blood Institute (NHLBI). WGS for “NHLBI 
TOPMed: Multi-Ethnic Study of Atherosclerosis (MESA)” (phs001416.v1.p1) was performed at the 
Broad Institute of MIT and Harvard (3U54HG003067-13S1). Centralized read mapping and genotype 
calling, along with variant quality metrics and filtering were provided by the TOPMed Informatics 
Research Center (3R01HL-117626-02S1). Phenotype harmonization, data management, sample-
identity QC, and general study coordination, were provided by the TOPMed Data Coordinating Center 
(3R01HL-120393-02S1). MESA and the MESA SHARe project are conducted and supported by the 
National Heart, Lung, and Blood Institute (NHLBI) in collaboration with MESA investigators. Support 
for MESA is provided by contracts HHSN268201500003I, N01-HC-95159, N01-HC-95160, N01-HC-
95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-
95167, N01-HC-95168, N01-HC-95169, UL1-TR-000040, UL1-TR-001079, UL1-TR-001420. MESA 
Family is conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in 
collaboration with MESA investigators. Support is provided by grants and contracts R01HL071051, 
R01HL071205, R01HL071250, R01HL071251, R01HL071258, R01HL071259, and by the National 
Center for Research Resources, Grant UL1RR033176. The provision of genotyping data was 
supported in part by the National Center for Advancing Translational Sciences, CTSI grant 
UL1TR001881, and the National Institute of Diabetes and Digestive and Kidney Disease Diabetes 
Research Center (DRC) grant DK063491 to the Southern California Diabetes Endocrinology 
Research Center. 
 
Massachusetts General Hospital Atrial Fibrillation Study (MGH_AF, 683) 
TOPMed dbGaP accession#: phs001062, Parent dbGaP accession#: phs001001 
The Massachusetts General Hospital (MGH) Atrial Fibrillation Study was initiated in 2001.32, 33 
The study has enrolled serial probands, unaffected and affected family members with atrial fibrillation. 
At enrollment participants undergo a structured interview to systematically capture their past medical 
history, AF treatments, and family history. An electrocardiogram is performed; the results of an 
echocardiogram are obtained; and blood samples are obtained. For the TOPMed whole genome 
sequencing project only early-onset atrial fibrillation cases were sequenced. Early-onset atrial 
fibrillation was defined as an age of onset prior to 66 years of age. 
 The MGH AF Study was supported by grants to Dr. Ellinor from the Fondation Leducq 
(14CVD01), the National Institutes of Health to Dr. Ellinor (1RO1HL092577, R01HL128914, 
K24HL105780) and Dr. Lubitz (1R01HL139731) and by grants from the American Heart Association 
to Dr. Ellinor (18SFRN34110082) and to Dr. Lubitz (18SFRN34250007). WGS for “NHLBI TOPMed: 
Massachusetts General Hospital Atrial Fibrillation Study” (phs001062) was performed at the Broad 
Institute of MIT and Harvard (3R01HL092577-06S1, 3U54HG003067-12S2, 3U54HG003067-13S1, 
and 3UM1HG008895-01S2) 
 
San Antonio Family Study (SAFS, 617) 
TOPMed dbGaP accession#: phs001215, Parent dbGaP accession#: phs000462 
 The San Antonio Family Heart Study is a complex pedigree-based mixed longitudinal study 
designed to identify low frequency or rare variants influencing susceptibility to cardiovascular disease, 
using whole genome sequence (WGS) information from 3,000 individuals in large Mexican American 
pedigrees from San Antonio, Texas.34 The major objectives of this study are to identify low frequency 
or rare variants in and around known common variant signals for CVD, as well as to find novel low 
frequency or rare variants influencing susceptibility to CVD. The study began in 1991, and included 
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1,431 individuals in 42 extended families at baseline. Probands were 40 to 60 year old low-income 
Mexican Americans selected at random without regard to presence or absence of disease, almost 
exclusively from Mexican American census tracts in San Antonio, Texas. All first, second, and third -
degree relatives of the proband and of the proband's spouse, aged 16 years or above, were eligible to 
participate in the study. 1,200 WGS at 30X WGS were obtained through Illumina funded by a 
supplement as part of the NHLBI's TOPMed program. 
Collection of the San Antonio Family Study data was supported in part by National Institutes of 
Health (NIH) grants R01 HL045522, MH078143, MH078111 and MH083824; and whole genome 
sequencing of SAFS subjects was supported by U01 DK085524 and R01 HL113323. We are very 
grateful to the participants of the San Antonio Family Study for their continued involvement in our 
research programs. WGS for “NHLBI TOPMed: Whole Genome Sequencing to Identify Causal 
Genetic Variants Influencing CVD Risk - San Antonio Family Studies” (phs001215) was performed at 
Illumina (3R01HL113323-03S1 and R01HL113322). 
 
Samoan Adiposity Study (Samoan, 1,182) 
TOPMed dbGaP accession#: phs000972, Parent dbGaP accession#: phs000914 
 The research goal of the Samoan Adiposity Study is to identify genetic variation that increases 
susceptibility to obesity and cardiometabolic phenotypes among adult Samoans using genome-wide 
association (GWAS) methods.35, 36 DNA from peripheral blood and phenotypic information were 
collected from 3,119 adult Samoans, 23 to 70 years of age. The participants reside throughout the 
independent nation of Samoa, which is experiencing economic development and the nutrition 
transition. Genotyping was performed with the Affymetrix Genome-Wide Human SNP 6.0 Array using 
a panel of approximately 900,000 SNPs. Anthropometric, fasting blood biomarkers and detailed 
dietary, physical activity, health and socio-demographic variables were collected. Whole genome 
sequencing of a subset was motivated by the opportunity to create a Samoan-specific reference 
panel for imputation into the larger parent study. 
Data collection was funded by NIH grant R01-HL093093. WGS for “NHLBI TOPMed: Samoan 
Adiposity Study” (phs000972) was performed at the University of Washington Northwest Genomics 
Center (HHSN268201100037C and HHSN268201500016C). We thank the Samoan participants of 
the study and local village authorities. We acknowledge the support of the Samoan Ministry of Health 
and the Samoa Bureau of Statistics for their support of this research. 
 
Taiwan Study of Hypertension using Rare Variants (THRV, 1,979) 
TOPMed dbGaP accession#: phs001387, Parent dbGaP accession#: phs001387 
The THRV-TOPMed study consists of three cohorts: The SAPPHIRe Family cohort (N=1,271), 
TSGH (Tri-Service General Hospital, a hospital-based cohort, N=160), and TCVGH (Taichung 
Veterans General Hospital, another hospital-based cohort, N=922), all based in Taiwan.37, 38 1,271 
subjects were previously recruited as part of the NHLBI-sponsored SAPPHIRe Network (which is part 
of the Family Blood Pressure Program, FBPP). The SAPPHIRe families were recruited to have two or 
more hypertensive sibs, some families also with one normotensive/hypotensive sib. The two Hospital-
based cohorts (TSGH and TCVGH) both recruited unrelated subjects with different recruitment 
criteria (matched with SAPPHIRe subjects for age, sex, and BMI category). 
The Rare Variants for Hypertension in Taiwan Chinese (THRV) is supported by the National Heart, 
Lung, and Blood Institute (NHLBI) grant (R01HL111249) and its participation in TOPMed is supported 
by an NHLBI supplement (R01HL111249-04S1). THRV is a collaborative study between Washington 
University in St. Louis, LA BioMed at Harbor UCLA, University of Texas in Houston, Taichung 
Veterans General Hospital, Taipei Veterans General Hospital, Tri-Service General Hospital, National 
Health Research Institutes, National Taiwan University, and Baylor University. THRV is based 
(substantially) on the parent SAPPHIRe study, along with additional population-based and hospital-
based cohorts. SAPPHIRe was supported by NHLBI grants (U01HL54527, U01HL54498) and Taiwan 
funds, and the other cohorts were supported by Taiwan funds.  WGS for “NHLBI TOPMed: Taiwan 
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Study of Hypertension using Rare Variants” (phs001387) was performed at the Baylor College of 
Medicine Human Genome Sequencing Center (3R01HL111249-04S1, HHSN26820150015C) 
 
Women’s Health Initiative (WHI, 8,305) 
TOPMed dbGaP accession#: phs001237, Parent dbGaP accession#: phs000200 
The Women's Health Initiative (WHI) is a long-term national health study that has focused on 
strategies for preventing heart disease, breast and colorectal cancer, and osteoporotic fractures in 
postmenopausal women (clinicaltrials.gov NCT00000611).39, 40, 41 The original WHI study included 
161,808 postmenopausal women enrolled between 1993 and 1998. The Fred Hutchinson Cancer 
Research Center in Seattle, WA serves as the WHI Clinical Coordinating Center for data collection, 
management, and analysis of the WHI. The WHI has two major parts: a partial factorial randomized 
Clinical Trial (CT) and an Observational Study (OS); both were conducted at 40 Clinical Centers 
nationwide. The CT enrolled 68,132 postmenopausal women between the ages of 50-79 into trials 
testing three prevention strategies. If eligible, women could choose to enroll in one, two, or all three of 
the trial components. The components are: hormone therapy trials, dietary modification trial, and 
calcium / vitamin D trial. The Observational Study (OS) examines the relationship between lifestyle, 
environmental, medical and molecular risk factors and specific measures of health or disease 
outcomes. This component involves tracking the medical history and health habits of 93,676 women 
not participating in the CT. Recruitment for the observational study was completed in 1998 and 
participants were followed annually for 8 to 12 years. 
The WHI program is funded by the National Heart, Lung, and Blood Institute, National 
Institutes of Health, U.S. Department of Health and Human Services through contracts 
HHSN268201600018C, HHSN268201600001C, HHSN268201600002C, HHSN268201600003C, and 
HHSN268201600004C. WGS for “NHLBI TOPMed: Women's Health Initiative” (phs001237) was 
performed at the Broad Institute of MIT and Harvard (HHSN268201500014C) 
 
Supplementary Note 2. HUNT (external to TOPMed) 
 The Trøndelag Health Study (The HUNT Study) is a collaboration between HUNT Research 
Centre (Faculty of Medicine, Norwegian University of Science and Technology NTNU), Nord-
Trøndelag County Council, Central Norway Health Authority, and the Norwegian Institute of Public 
Health. The HUNT-MI study, which comprises the genetic investigations of the HUNT Study, is a 
collaboration between investigators from the HUNT study, University of Michigan School of Public 
Health and Michigan Medicine.  The K.G. Jebsen Center for Genetic Epidemiology is financed by 
Stiftelsen Kristian Gerhard Jebsen; Faculty of Medicine and Health Sciences, NTNU, Norwegian 
University of Science and Technology (NTNU) and Central Norway Regional Health Authority.  We 




Supplementary Note 3. UK Biobank (external to TOPMed) 
The UK Biobank analyses were conducted using the UK Biobank resource under application 
7089. 
 
Supplementary Note 4. FinnGen (external to TOPMed) 
The FinnGen project is funded by two grants from Business Finland (HUS 4685/31/2016 and 
UH 4386/31/2016) and eleven industry partners (AbbVie Inc, AstraZeneca UK Ltd, Biogen MA Inc, 
Celgene Corporation, Celgene International II Sàrl, Genentech Inc, Merck Sharp & Dohme Corp, Pfizer 
Inc., GlaxoSmithKline, Sanofi, Maze Therapeutics Inc., Janssen Biotech Inc). Following biobanks are 
acknowledged for delivering biobank samples to FinnGen: Auria Biobank (www.auria.fi/biopankki), THL 
Biobank (www.thl.fi/biobank), Helsinki Biobank (www.helsinginbiopankki.fi), Biobank Borealis of 
Northern Finland (https://www.ppshp.fi/Tutkimus-ja-opetus/Biopankki/Pages/Biobank-Borealis-briefly-
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in-English.aspx), Finnish Clinical Biobank Tampere (www.tays.fi/en-
US/Research_and_development/Finnish_Clinical_Biobank_Tampere), Biobank of Eastern Finland 
(www.ita-suomenbiopankki.fi/en), Central Finland Biobank (www.ksshp.fi/fi-FI/Potilaalle/Biopankki), 
Finnish Red Cross Blood Service Biobank (www.veripalvelu.fi/verenluovutus/biopankkitoiminta) and 
Terveystalo Biobank (www.terveystalo.com/fi/Yritystietoa/Terveystalo-Biopankki/Biopankki/).  All 
Finnish Biobanks are members of BBMRI.fi infrastructure (www.bbmri.fi). 
Patients and control subjects in FinnGen provided informed consent for biobank research, based 
on the Finnish Biobank Act. Alternatively, separate research cohorts, collected prior the Finnish 
Biobank Act came into effect (in September 2013) and start of FinnGen (August 2017), were collected 
based on study-specific consents and later transferred to the Finnish biobanks after approval by Fimea, 
the National Supervisory Authority for Welfare and Health. Recruitment protocols followed the biobank 
protocols approved by Fimea. The Coordinating Ethics Committee of the Hospital District of Helsinki 
and Uusimaa (HUS) approved the FinnGen study protocol Nr HUS/990/2017. 
The FinnGen project is approved by Finnish Institute for Health and Welfare (THL), approval 
number THL/2031/6.02.00/2017, amendments THL/1101/5.05.00/2017, THL/341/6.02.00/2018, 
THL/2222/6.02.00/2018, THL/283/6.02.00/2019), Digital and population data service agency 
VRK43431/2017-3, VRK/6909/2018-3, the Social Insurance Institution (KELA) KELA 58/522/2017, 
KELA 131/522/2018, KELA 70/522/2019 and Statistics Finland TK-53-1041-17.  
The Biobank Access Decisions for FinnGen samples and data utilized in FinnGen Data Freeze 
4 include: THL Biobank BB2017_55, BB2017_111, BB2018_19, BB_2018_34, BB_2018_67, 
BB2018_71, BB2019_7 Finnish Red Cross Blood Service Biobank 7.12.2017, Helsinki Biobank 
HUS/359/2017, Auria Biobank AB17-5154, Biobank Borealis of Northern Finland_2017_1013,  Biobank 
of Eastern Finland 1186/2018, Finnish Clinical Biobank Tampere MH0004, Central Finland Biobank 1-
2017, and Terveystalo Biobank STB 2018001.  
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Supplementary Table 1. Baseline characteristics of TOPMed participants in discovery genetic 
association analyses by cohort. 
 





































































































































































































































0 (0%) 0 (0%) 0 (0%) 
1,770 
(100%) 
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Age and cholesterol values are expressed as mean(SD), triglyceride values are expressed as 
median[Q1-Q3], and count data are expressed as N(%). 
AFR = African; AI_AN = American Indian/Alaskan Native/Native American; ASN = Asian; EUR = 
European; F = female; HDL = high-density lipoprotein; HIS = Hispanic; LDL = low-density lipoprotein; 




Supplementary Table 2. Baseline characteristics of TOPMed participants in discovery genetic 
association analyses by reported ancestry. 
 
Ancestry Total Age Sex 
Cholesterol 
TG Lipid Rx 

























































































































Age and cholesterol values are expressed as mean(SD), triglyceride values are expressed as 
median[Q1-Q3], and count data are expressed as N(%). 
AFR = African; AI_AN = American Indian/Alaskan Native/Native American; ASN = Asian; EUR = 
European; HDL = high-density lipoprotein; HIS = Hispanic; LDL = low-density lipoprotein; Rx = 
prescription; SAM = Samoan; TG = triglycerides. 
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Supplementary Table 3. Chromosome X variant characteristics per sample by TOPMed cohort 
and sex. 
 Females Males 

























































































































































































































































































































































































































































Each continuous metric is expressed as mean (standard deviation) 
Het/Hom = heterozygous to homozygous genotype counts ratio; Ti/Tv = transition to transversion 
ratio
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MAC 1 MAC 2 MAC 3 










ARIC 7,991 2051998 1143815 394437 860633 577744 202822 229316 5460753 
Amish 1,083 22138 6626 6680 315 59658 62967 188117 339771 
BioMe 9,857 2680736 1321112 433579 1132870 631761 241641 209571 6706481 
CARDIA 3,054 1389391 695923 211048 279006 587968 242094 266061 3671461 
CFS 577 221372 158424 108510 141 583262 258958 226277 1345648 
CHS 2,773 1115677 553667 181076 189200 504375 125243 197897 2867100 
DHS 365 277382 212828 88139 0 750407 263009 329041 1342457 
FHS 3,990 456418 418354 306156 390861 330507 93721 192568 2188568 
GENOA 1,044 383318 259601 145846 339 612628 269346 331328 1854909 
GOLDN 924 169868 128692 80658 816  446607 97517 191126 905820 
GenSalt 1,770 329836 322992 166274 1331 422154 79343 171831 1504385 
GeneSTAR 1,755 413416 305167 213395 217 713325 244469 210789 2155445 
HCHS/SOL 7,391 1671675 966190 398811 950681 601789 200875 235186 5025198 
HyperGEN 1,853 535092 377520 178153 326 695870 266958 330064 2383533 
JHS 2,846 867925 487481 221111 247702 638633 265387 329783 3057921 
MESA 5,283 1790587 1099057 356976 708748 634608 232612 201206 5077793 
MGH_AF 683 211977 332494 46424 833 530222 97302 192815 1032912 
SAFS 617 192778 115913 82326 553 422217 121482 193163 929868 
Samoan 1,182 217671 94428 50323 2824 176247 58251 170138 719369 
THRV 1,979 424305 325744 128603 1576 440456 80582 170204 1571286 
WHI 8,305 4006130 846434 356194 826728 569312 179812 217275 7001877 
Across All 
Studies 
65,322 7375647 3867043 1776661 5792496 620628 220071 245123 19897667 
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Supplementary Table 5. Chromosome X variants showing at least suggestive evidence of association with blood lipids in 
TOPMed and the evidence of replication in UK Biobank and HUNT. 




AAF Beta SE P rsID AAF Beta SE P AAF Beta SE P 
TC rs5942634 chrX:110464413:A:T 0.344 -1.95 0.237 2.00E-16 rs5942634 0.387 -1.194 0.0819 3.59E-48 0.382 -1.2410 0.198 3.4E-10 
 rs185814586 chrX:154690417:C:G 0.0391 -3.627 0.593 9.74E-10 rs185814586 0.003 9.803 6.9291 1.57E-01 N/A 
 rs145493495 chrX:93454733:C:T 0.0062 -7.697 1.406 4.40E-08 rs145493495 0.0004 -6.973 9.9419 0.4831 N/A 
 rs138747372 chrX:32141527:A:G 0.0046 -8.221 1.626 4.28E-07 rs138747372 0.0003 37.499 20.4953 0.0673 N/A 
 rs781790319 chrX:143911300:G:A 0.0006 21.53 4.294 5.33E-07 rs781790319 0.00006 17.729 8.5473 0.0381 N/A 
                
Log(TG) rs5985504 chrX:110605767:T:C 0.5673 0.0188 0.0029 4.16E-11 rs5985504 0.602 0.0116 0.00099 2.15E-31 0.601 0.0123 0.002 4.30E-07 
 rs183294530 chrX:94076540:G:A 0.0023 0.1494 0.0273 4.38E-08 rs183294530 0.002 -0.0059 0.01127 5.98E-01 N/A 
 rs921187255 chrX:54528114:C:T 0.000173 -0.536 0.1034 2.18E-07 no proxy N/A 
 rs777673958 chrX:70371648:G:T 0.00098 0.2123 0.0411 2.40E-07 no proxy N/A 
 rs187325394 chrX:134877208:A:G 0.0004 -0.3185 0.0629 4.02E-07 rs187325394 0.0009 -0.1816 0.0944 5.44E-02 N/A 
  chrX:117213036:C:T 0.0002 -0.5098 0.1016 5.22E-07 no proxy N/A 
 rs754747891 chrX:79229651:T:A 0.0003 0.4158 0.0835 6.30E-07 rs749043821 0.00005 N/A N/A 
 rs942975446 chrX:47314065:C:T 0.0002 0.4987 0.1016 9.21E-07 no proxy N/A 
                
HDL-C rs988403543 chrX:111037797:A:T 0.0002 14.466 2.57573 1.95E-08 no proxy N/A 
 rs902277370 chrX:104738300:G:T 0.0002 13.89 2.64339 1.48E-07 no proxy N/A 
 rs966434643 chrX:85687610:C:T 0.00015 14.97 2.96778 4.56E-07 no proxy N/A 
 rs5935802 chrX:14723826:C:T 0.442 0.4044 0.08221 8.69E-07 rs5935802 0.564 0.1228 0.0277 9.44E-06 0.57 0.0685 0.062 0.27 
                
LDL-C rs5942648 chrX:110545499:G:A 0.3827 -1.529 0.215 1.19E-12 rs5942648 0.391 -1.016 0.0643 3.81E-56 0.384 -0.8934 0.181 7.40E-07 
 rs201851580 chrX:154959385:C:CA 0.0354 -3.548 0.574 6.42E-10 rs201851580 0.004 0.472 1.261 7.08E-01 N/A 
 rs750131104 chrX:65851068:T:C 0.0041 8.103 1.559 2.01E-07 rs750131104 0.0002 -3.676 32.209 9.09E-01 N/A 
 rs182564432 chrX:145894241:T:C 0.0007 -19.815 3.843 2.52E-07 rs182564432 0.00003 N/A N/A 
 
Top chromosome X variants at loci showing at least suggestive evidence (P<1x10-6) of association with lipids in TOPMed are displayed. 
Distinct loci are defined by +/- 400 kb window surrounding the lowest P. If variants prioritized by TOPMed chromosome X sequencing 
are not genotyped or imputed in UK Biobank chromosome X array genotyping, suitable proxies are used when present (LD r2 > 0.8). 
Effect estimates for triglycerides are on the natural log scale. 
AAF = alternative allele frequency; LD = linkage disequilibrium; P = p-value; SE = standard error; TOPMed = Trans-Omics for Precision 
Medicine
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Age (y) 56.9 (7.9) 
Sex 179,963 (46.1%) 
European ancestry 376,358 (96.4%) 
Cholesterol (mg/dl)  
   Total 221.1 (44.3) 
   HDL 56.1 (14.8) 
   LDL 138.1 (33.7) 
Triglycerides (mg/dl) 132.6 [93.6-191.5] 
Statin Rx 64,004 (16.4%) 
BMI (kg/m2) 27.4 (4.8) 
Systolic blood pressure (mmHg) 140.2 (19.7) 
Diastolic blood pressure (mmHg) 82.3 (10.7) 
Current smoker 39,736 (10.2%) 
Diabetes mellitus type 2 25,349 (6.5%) 
Coronary artery disease 18,204 (4.8%) 
 
Continuous values are presented as mean (standard deviation) except for triglycerides which is given 
as median (Q1-Q3) due to the skewness of the triglyceride distribution. Categorical data are 
presented as count (percentage). 
BMI = body mass index; HDL = high-density lipoprotein; LDL = low-density lipoprotein  
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Supplementary Table 7. Baseline characteristics of HUNT participants in replication analyses. 
 
Metric Value 
Age (y) 47.9 (16.9) 
Sex 36,907 (53.0%) 
European ancestry 69,635 (100%) 
Cholesterol (mg/dl)  
   Total 222.5 (48.6) 
   HDL 52.8 (14.7) 
   LDL 139.9 (42.8) 
Triglycerides (mg/dl) 152.6 (99.9) 
Statin Rx NA 
BMI (kg/m2) 26.3 (4.2) 
Systolic blood pressure (mmHg) 135.1 (21.1) 
Diastolic blood pressure (mmHg) 78.5 (12.5) 
Current smoker 6,480 
Diabetes mellitus type 2 5,382 (7.7%) 
Coronary artery disease 7,710 (11.6%) 
 
Continuous values are presented as mean (standard deviation) and categorical data are presented as 
count (percentage). 
BMI = body mass index; HDL = high-density lipoprotein; LDL = low-density lipoprotein   
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Supplementary Table 8. Pairwise linkage disequilibrium of chrXq23 variants associated with 
lipid levels in TOPMed. 
 
 rs5985504 rs5942634 rs5942648 
rs5985504 1.00 0.61 0.73 
rs5942634 0.61 1.00 0.84 
rs5942648 0.73 0.84 1.00 
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Supplementary Table 9. Lipid effect estimates within TOPMed by sex for chrXq23 associated 
variants 
 
  Males Females I2, P for 
heterogeneity 
Variant Trait Beta±SE P Beta±SE P  
rs5985504 Triglycerides -0.025±0.0041 7.3x10-10 -0.01±0.0040 6.3 x10-3 I2 = 85.4%,  
P = 0.0088 
rs5942634 Total 
cholesterol 
-1.91±0.31 1.8x10-9 -1.84±0.34 6.7x10-8 I2 = 0%,  
P = 0.8791 
rs5942648 LDL-C -1.53±0.29 1.0x10-7 -1.74±0.32 3.4x10-6 I2 = 0%,  
P = 0.6268 
 
Effect estimate for Total cholesterol and LDL-C are in mg/dl units while effect estimates for 
triglycerides are in log(mg/dl) units. Linear regression association analyses were adjusted for age, 
age2, batch, and principal components, as well as study-specific covariates where appropriate. P-
values presented are two-sided without further adjustment for this secondary analyses. 
LDL-C = low-density lipoprotein cholesterol; SE = standard error. 
  
 22 
Supplementary Table 10. Ancestry-specific allele frequencies and effect estimates for 
associated chrXq23 variants with total cholesterol in TOPMed. 
 
Ancestry AN 
rs5942634-T rs5942648-A rs5985504-T 
AF Beta SE P AF Beta SE P AF Beta SE P 
ASN 402 0.02 -2.46 2.22 0.27 0.02 -2.46 2.22 0.27 0.02 -2.03 2.31 0.38 
AFR 25192 0.38 -1.44 0.46 1.7x10-3 0.50 -1.52 0.44 5.98x10-4 0.67 -1.74 0.47 2.50x10-4 
HIS 16382 0.31 -1.99 0.57 4.6x10-4 0.34 -1.84 0.55 8.64x10-3 0.37 -1.75 0.55 1.52x10-3 
SAM 64 0.01 -3.01 5.83 0.61 0.01 -3.01 5.83 0.61 0.01 -1.37 5.78 0.81 
EUR 47694 0.41 -2.04 0.32 1.06x10-10 0.41 -1.95 0.31 5.79x10-10 0.41 -1.85 0.31 4.40x10-9 
Test of Heterogeneity 
across ancestries I2 = 0.0%, P = 0.860 I2 = 0.0%, P = 0.943 I2 = 0.0%, P = 0.999 
 
Linear regression association analyses were adjusted for age, age2, sex, batch, and principal 
components, as well as study-specific covariates where appropriate. P-values presented are two-
sided without further adjustment for this secondary analyses. AF = allele frequency; AFR = African; 




Supplementary Table 11. Results for association with total cholesterol in conditional analysis 
with TOPMed samples. 
 
SNP Ref Alt Beta SE P 
SNPs individually in model 
rs5942634 A T -1.950 0.237 2.00E-16 
rs5985471 C T -1.714 0.235 3.21E-13 
rs5942937 T G -1.623 0.239 1.02E-11 
rs5943057 T G -1.685 0.246 7.11E-12 
Adjusting for rs5942634 
rs5985471 C T -0.176 0.387 0.649 
rs5942937 T G 0.291 0.426 0.4952 
rs5943057 T G -0.309 0.363 0.3937 
Adjusting for rs5985471, rs5942937, and rs5943057 
rs5942634 A T -1.614 0.453 0.000368 
 
Linear regression association analyses were adjusted for age, age2, sex, batch, and principal 
components, as well as study-specific covariates where appropriate. P-values presented are two-








Age (y) 59.39 (17.35) 
Sex 76,538 (43.27%) 
European ancestry 176,899 (100%) 
Hypercholesterolemia 10,041 (5.88%) 
Cholesterol (mg/dl) 
 
  Total NA 
  HDL NA 
  LDL NA 
Triglycerides (mg/dl) NA 
Statin Rx 53,518 (30.25%) 
BMI (kg/m2) 27.16 (5.26) 
Hypertension 43,545 (24.62%) 
Current smoker 948 (0.82%) 
Diabetes mellitus type 2 23,364 (13.65) 
Coronary artery disease 16,631 (9.4%) 
  
Continuous values are presented as mean (standard deviation) and categorical data are presented as 
count (percentage). 
BMI = body mass index; HDL = high-density lipoprotein; LDL = low-density lipoprotein   
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Supplementary Table 13. Definitions of traits and conditions analyzed in phenome-wide 
association analyses.  
 
Clinical Phenotype Definition 
Heart failure 
Self-reported history of heart failure or cardiomyopathy during verbal interview 
with trained nurse; or hospitalization with or death due to ICD-10 code for 
hypertensive heart disease, cardiomyopathy or heart failure (I11.0, I13.0, 
I13.2, I25.5, I42.0, I42.5, I42.8, I42.9, I50.0, I50.1, I50.9); or hospitalization 
with ICD-9 code for heart failure or other primary cardiomyopathies (4254, 
4280, 4281, 4289); excluding individuals with history of hypertrophic 
cardiomyopathy during verbal interview with trained nurse, or hospitalization 




Self-reported history of hypertrophic cardiomyopathy during a verbal interview 
with a trained nurse; or hospitalization or death due to an ICD-10 code for 
hypertrophic cardiomyopathy (I42.1, I42.2); or hospitalization with an ICD-9 
code for hypertrophic cardiomyopathy (425.11, 425.18). 
Coronary artery disease 
Self-reported history of myocardial infarction (MI), coronary artery bypass 
grafting, coronary artery angioplasty or triple heart bypass during verbal 
interview with trained nurse; or hospitalization with or death due to ICD-10 
code for acute or subsequent myocardial infarction (I21, I22, I23, I24.1, I25.2); 
or hospitalization with ICD-9 code for myocardial infarction (410, 411, 412); or 
hospitalization with OPCS-4 code for coronary artery bypass grafting (K40, 
K41, K45) or coronary angioplasty ± stenting (K49, K50.2, K75) 
Stroke 
Self-reported history of stroke during verbal interview with trained nurse; or 
hospitalization with or death due to ICD-10 code for nontraumatic 
subarachnoid hemorrhage, nontraumatic intracerebral hemorrhage, cerebral 
infarction, or unspecified stroke (I60-64); or hospitalization with or death due to 
ICD-9 code for subarachnoid hemorrhage, intracerebral hemorrhage, 
occlusion of cerebral arteries, or acute cerebrovascular disease (430, 431, 
434, 436), as adjudicated centrally by the UK Biobank 
(http://biobank.ctsu.ox.ac.uk/crystal/refer.cgi?id=462) 
Ischemic stroke 
Self-reported history of ischemic stroke during verbal interview with trained 
nurse; or hospitalization with or death due to ICD-10 code for cerebral 
infarction, or unspecified stroke (I63, 64); or hospitalization with or death due 
to ICD-9 code for occlusion of cerebral arteries or acute cerebrovascular 
disease (434, 436), as adjudicated centrally by the UK Biobank 
(http://biobank.ctsu.ox.ac.uk/crystal/refer.cgi?id=462) 
Intracerebral hemorrhage 
Self-reported history of brain hemorrhage during verbal interview with trained 
nurse; or hospitalization with or death due to ICD-10 code for nontraumatic 
intracerebral hemorrhage (I61); or hospitalization with or death due to ICD-9 
code for intracerebral hemorrhage (431), as adjudicated centrally by the UK 
Biobank (http://biobank.ctsu.ox.ac.uk/crystal/refer.cgi?id=462) 
Pulmonary hypertension 
Hospitalization with or death due to ICD-10 code for primary or other 
secondary pulmonary hypertension (I27.0, I27.2); or hospitalization with ICD-9 
code for primary pulmonary hypertension (4160) 
 
Atrial fibrillation or flutter 
Self-reported history of atrial fibrillation, atrial flutter, or cardioversion during 
verbal interview with trained nurse; or hospitalization with or death due to ICD-
10 code for atrial fibrillation or atrial flutter (I48); or hospitalization with ICD-9 
code for atrial fibrillation or atrial flutter (4273); or hospitalization with OPCS-4 
code for percutaneous transluminal ablation (K57.1, K 62.1, K62.2, K62.3, 
K62.4) 
Venous thromboembolism 
Self-reported history of venous thromboembolic disease, pulmonary embolism 
or deep venous thrombosis during verbal interview with trained nurse; or 
hospitalization with or death due to ICD-10 code for pulmonary embolism (I26), 
phlebitis or thrombophlebitis (I80.0-I80.3, I80.8-I80.9), portal vein thrombosis 
(I81), Budd-Chiari syndrome (I82.0), or other coagulation defects (D68); or 
hospitalization with ICD-9 code for pulmonary embolism or 
phlebitis/thrombophlebitis (4151, 4511); or hospitalization with OPCS-4 code 
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for insertion of inferior vena cava filter or open thrombectomy of lower 
extremity vein (L79.1, L90.2) 
Peripheral vascular disease 
Self-reported history of peripheral vascular disease, arterial embolism, 
intermittent claudication, leg artery bypass, leg artery angioplasty, or leg 
amputation during verbal interview with trained nurse;  or hospitalization with 
or death due to ICD-10 code for atherosclerosis of (non-coronary) arteries or 
peripheral vascular disease (I70.0, I70.00, I70.01, I70.2, I70.20, I70.21, I70.8, 
I70.80, I70.9, I70.90, I73.8 or I73.9); or hospitalization with ICD-9 code for 
atherosclerosis of arteries or peripheral vascular disease (4400, 4402, 4438, 
4439); or hospitalization with OPCS-4 coded procedure for leg amputation, or 
leg artery procedure such as bypass, stent or angioplasty (X09.3-09.5, L21.6, 
L51.3, L51.6, L51.8, L52.1, L52.2, L54.1, L54.4, L54.8, L59.1-L59.8, L60.1, 
L60.2, L63.1, L63.5, L63.9, L66.7) 
Hypertension 
Self-reported history of hypertension, essential hypertension or high blood 
pressure during verbal interview with trained nurse; or hospitalization with or 
death due to ICD-10 code for essential hypertension, hypertensive heart 
disease, hypertensive renal disease, or secondary hypertension (I10, I11, I12, 
I13, I15); or hospitalization with ICD-9 code for essential hypertension, 
hypertensive heart disease, hypertensive renal disease, or secondary 
hypertension (401, 402, 403, 404, 405) 
Hypercholesterolemia 
Self-reported history of high cholesterol during verbal interview with trained 
nurse; or hospitalization with or death due to ICD-10 code for 
hypercholesterolemia, hypertriglyceridemia, or hyperlipidemia (E78.0-E78.2, 
E78.4, E78.5) 
Supraventricular arrhythmia 
–general inclusive definition 
Self-reported history of Wolff-Parkinson-White syndrome or supraventricular 
tachycardia during verbal interview with trained nurse;  or hospitalization with 
or death due to ICD-10 code for Preexcitation syndrome, supraventricular 
tachycardia, atrial premature depolarization (I45.6, I47.1, I49.1); or 
hospitalization with ICD-9 code for anomalous atrioventricular excitation or 
paroxysmal supraventricular tachycardia (4267, 4270); or hospitalization with 
OPCS-4 coded procedure for open division of accessory pathway, 
percutaneous transluminal ablation of accessory pathway/atrial 
wall/conduction system (K52.4, K57.2, K57.4, K57.5) 
Bradyarrhythmia – sinus 
node dysfunction 
Self-reported history of sick sinus syndrome during verbal interview with 
trained nurse;  or hospitalization with or death due to ICD-10 code for sick 
sinus syndrome (I49.5) 
Bradyarrhythmia - AV block / 
distal conduction disease 
Hospitalization with or death due to ICD-10 code for atrioventricular and 
intraventricular block (I44, I45.0-I45.5); or hospitalization with ICD-9 code for 
atrioventricular or intraventricular block (4260, 4261, 4263, 4264, 4265, 4266) 
Ventricular arrhythmia - 
General inclusive definition 
Hospitalization with or death due to ICD-10 code for ventricular arrhythmias, 
ventricular premature depolarization or cardiac arrest (I46.0, I46.1, I46.9, I47.0, 
I47.2, I49.0, I49.3); or hospitalization with ICD-9 code for ventricular 
arrhythmias or cardiac arrest (4271, 4274, 4275); or hospitalization with 
OPCS-4 coded procedure for percutaneous transluminal/radiofrequency 
ablation (K57.6, K64.1) or resuscitation/defibrillation (X50.3, X50.4, X50.8, 
X50.9) 
Aortic stenosis 
Self-reported history of aortic stenosis during verbal interview with trained 
nurse; or hospitalization with or death due to ICD-10 code for rheumatic aortic 
stenosis (I06.0, I06.2) or nonrheumatic aortic stenosis (I35.0, I35.2) 
Aortic regurgitation 
Self-reported history of aortic regurgitation during verbal interview with trained 
nurse; or hospitalization with or death due to ICD-10 code for rheumatic aortic 
insufficiency (I06.1, I06.2) or nonrheumatic aortic insufficiency (I35.0, I35.2); or 
hospitalization with ICD-9 code for rheumatic aortic insufficiency (3951) 
Mitral stenosis 
Self-reported history of mitral stenosis during verbal interview with trained 
nurse; or hospitalization with or death due to ICD-10 code for rheumatic and 
nonrheumatic mitral stenosis (I05.0, I34.2); or hospitalization with ICD-9 code 
for mitral stenosis + insufficiency (3940, 3942); or hospitalization with OPCS-4 
code for percutaneous transluminal mitral valvotomy (K35.1) 
Mitral regurgitation 
Self-reported history of mitral regurgitation during verbal interview with trained 
nurse; or hospitalization with or death due to ICD-10 code for rheumatic and 
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nonrheumatic mitral insufficiency (I05.1, I05.2, I34.0); or hospitalization with 
ICD-9 code for mitral insufficiency (3942); or hospitalization with OPCS-4 code 
for mitral valve annuloplasty (K34.1) 
Mitral valve prolapse 
Self-reported history of mitral valve prolapse during verbal interview with 
trained nurse; or hospitalization with or death due to ICD-10 code for mitral 
valve prolapse (I34.1) 
Tricuspid stenosis 
Hospitalization with or death due to ICD-10 code for rheumatic and 
nonrheumatic tricuspid stenosis (I07.0, I07.2, I36.0) 
Tricuspid regurgitation 
Hospitalization with or death due to ICD-10 code for rheumatic and 
nonrheumatic tricuspid regurgitation (I07.1, I07.2, I36.1); or hospitalization with 
OPCS-4 code for tricuspid valve annuloplasty (K34.2) 
Pulmonary stenosis 
Hospitalization with or death due to ICD-10 code for pulmonary stenosis (I37.0, 
I37.2) 
Pulmonary regurgitation 
Hospitalization with or death due to ICD-10 code for pulmonary insufficiency 
(I37.1, I37.2) 
Congenital heart disease 
Hospitalization with or death due to ICD-10 code for congenital malformations 
of cardiac chambers/connexions, cardiac septa, 
aortic/mitral/tricuspid/pulmonary valves, and other/unspecified malformation 
(Q20.1, Q20.2, Q20.3, Q20.4, Q20.5, Q20.6, Q20.8, Q20.9; Q21, Q22, Q23, 
Q24); or hospitalization with ICD-9 code for congenital anomalies of the heart 
and cardiac septa (745, 746); or hospitalization with OPCS-4 code for repair of 
tetralogy of Fallot (K04), correction of total anomalous pulmonary venous 
connection (K07), repair of defect of 
atrioventricular/interatrial/interventricular/unspecified septum (K09, K10, K11, 
K12), transluminal repair of septal defect (K13), transluminal repair of atrial 
septum or patent oval foramen with prosthesis (K16.3, K16.5), creation of 
valved/other cardiac conduit (K18, K19, refashioning of atrium (K20) 
Diabetes mellitus, type 1 
Self-reported history of Type 1 diabetes during verbal interview with trained 
nurse; or hospitalization with or death due to ICD-10 code for insulin-
dependent diabetes mellitus (E10) 
Diabetes mellitus, type 2 
Self-reported history of type 2 diabetes during verbal interview with trained 
nurse; or hospitalization with or death due to ICD-10 code for non-insulin-
dependent diabetes mellitus (E11) 
Diabetes mellitus, all 
Self-reported history of diabetes, gestational diabetes, type 1/type 2 or insulin 
use during verbal interview with trained nurse; or hospitalization with or death 
due to ICD-10 code for insulin-dependent and non-insulin-dependent diabetes 
mellitus (E10, E11), malnutrition-related diabetes mellitus (E12), other 
specified/unspecified diabetes mellitus (E13, E14); or hospitalization with ICD-
9 code for diabetes mellitus with/without complications (2500, 2501, 2503, 
2504, 2505, 2509) 
Hyperthyroidism 
Self-reported history of hyperthyroidism/thyrotoxicosis during verbal interview 
with trained nurse; or hospitalization with or death due to ICD-10 code for 
hyperthyroidism/thyrotoxicosis (E05); or hospitalization with ICD-9 code for 
thyrotoxicosis with/without goiter (242) 
Hypothyroidism 
Self-reported history of hypothyroidism/myxoedema during verbal interview 
with trained nurse; or hospitalization with or death due to ICD-10 code for 
hypothyroidism (E03); or hospitalization with ICD-9 code for acquired 
hypothyroidism (244) 
Gout 
Self-reported history of gout during verbal interview with trained nurse; or 
hospitalization with or death due to ICD-10 code for gout (M10.0, M10.2, 
M10.3, M10.4, M10.9); or hospitalization with ICD-9 code for gout (274) 
Enlarged prostate 
Self-reported history of enlarged prostate during verbal interview with trained 
nurse; or hospitalization with or death due to ICD-10 code for hyperplasia of 
prostate (N40); or hospitalization with ICD-9 code for hyperplasia of prostate 
(600) 
Uterine fibroids 
Self-reported history of uterine fibroids or myomectomy/fibroid removal during 
verbal interview with trained nurse; or hospitalization with or death due to ICD-
10 code for leiomyoma of uterus (D25); or hospitalization with ICD-9 code for 
uterine leiomyoma (218) 
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Chronic kidney disease 
Self-reported history of kidney failure ± dialysis, kidney nephropathy, IgA 
nephropathy, diabetic nephropathy or kidney transplant during verbal interview 
with trained nurse; or hospitalization with or death due to ICD-10 code for 
hypertensive renal disease, chronic renal failure, end stage renal failure or 
chronic kidney disease (I12.0, I13.1, I13.2, N18, N18.0-18.5, N18.8, N18.9); or 
hospitalization with ICD-9 code due to chronic renal failure (585, 5859); or 
hospitalization with OPCS-4 coded procedure for kidney transplantation 
(M01.1-01.5, M01.8, M01.9) 
Gastroesophageal reflux 
disease 
Self-reported history of gastroesophageal/gastric reflux during verbal interview 
with trained nurse; or hospitalization with or death due to ICD-10 code for 
gastroesophageal reflux disease (K21); or hospitalization with ICD-9 code for 
esophageal reflux (53010, 53011) 
Irritable bowel syndrome 
Self-reported history of irritable bowel syndrome during verbal interview with 
trained nurse; or hospitalization with or death due to ICD-10 code for irritable 
bowel syndrome (K58); or hospitalization with ICD-9 code for irritable colon 
(5641) 
Cholelithiasis or Gallstones 
Self-reported history of cholelithiasis/gallstones or gallstone removal during 
verbal interview with trained nurse; or hospitalization with or death due to ICD-
10 code for gallstone ileus (K56.3) or cholelithiasis (K80; or hospitalization with 
ICD-9 code for cholelithiasis (574); or hospitalization with OPCS-4 coded 
procedure for open removal/percutaneous dissolution/fragmentation of gall 
bladder calculus (J21.1, J24.2, J24.3, J26.1) 
Inflammatory bowel disease 
Self-reported history of inflammatory bowel disease, Crohn’s disease, or 
ulcerative colitis during verbal interview with trained nurse; or hospitalization 
with or death due to ICD-10 code for Crohn’s disease or ulcerative colitis (K50, 
K51); or hospitalization with ICD-9 code for regional enteritis, idiopathic 
proctocolitis (555, 556) 
Diverticular disease 
Self-reported history of diverticular disease during verbal interview with trained 
nurse; or hospitalization with or death due to ICD-10 code for diverticular 
disease of intestine (K57); or hospitalization with ICD-9 code for diverticula of 
intestine (562) 
Pancreatitis 
Self-reported history of pancreatitis during verbal interview with trained nurse; 
or hospitalization with or death due to ICD-10 code for acute pancreatitis (K85) 
or alcohol-induced/other chronic pancreatitis (K86.0, K86.1); or hospitalization 
with ICD-9 code for acute/chronic pancreatitis (5770, 5771) 
Migraine 
Self-reported history of migraine during verbal interview with trained nurse; or 
hospitalization with or death due to ICD-10 code for migraine (G43) 
Depression 
Self-reported history of depression during verbal interview with trained nurse; 
or hospitalization with or death due to ICD-10 code for depressive episode or 
recurrent depressive disorder (F32, F33); or hospitalization with ICD-9 code 
for depressive disorder (3119) 
Bipolar disorder 
Self-reported history of mania/bipolar disorder/manic depression during verbal 
interview with trained nurse; or hospitalization with or death due to ICD-10 
code for bipolar affective disorder (F31) 
Anxiety 
Self-reported history of anxiety/panic attacks during verbal interview with 
trained nurse; or hospitalization with or death due to ICD-10 code for anxiety 
disorders (F41) 
Schizophrenia 
Self-reported history of schizophrenia during verbal interview with trained 




Self-reported history of post-traumatic stress disorder during verbal interview 
with trained nurse; or hospitalization with or death due to ICD-10 code for 
post-traumatic stress disorder (F43.1) 
Multiple sclerosis 
Self-reported history of multiple sclerosis during verbal interview with trained 
nurse; or hospitalization with or death due to ICD-10 code for multiple 
sclerosis (G35); or hospitalization with ICD-9 code for multiple sclerosis (3409) 
Parkinson’s disease 
Self-reported history of Parkinson’s disease during verbal interview with 
trained nurse; or hospitalization with or death due to ICD-10 code for 
Parkinson’s disease (G20) or dementia in Parkinson’s disease (F02.3); or 
hospitalization with ICD-9 code for paralysis agitans (3320) 
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Epilepsy 
Self-reported history of epilepsy during verbal interview with trained nurse; or 
hospitalization with or death due to ICD-10 code for epilepsy (G40); or 
hospitalization with ICD-9 code for epilepsy (3450, 3451, 3452, 3454, 3459) 
Alzheimer’s / Dementia 
Self-reported history of dementia/Alzheimer’s/cognitive impairment during 
verbal interview with trained nurse; or hospitalization with or death due to ICD-
10 code for dementia in Alzheimer’s disease (F00) 
Back pain 
Self-reported history of back pain or sciatica during verbal interview with 
trained nurse; or hospitalization with or death due to ICD-10 code for Dorsalgia 
(M54); or hospitalization with ICD-9 code for cervicalgia, spinal stenosis, pain 
in thoracic spine, lumbago, sciatica, thoracic or lumbosacral neuritis/radiculitis, 
unspecified backache (7231, 7240, 7241, 7242, 7243, 7244, 7245) 
Sciatica 
Self-reported history of sciatica during verbal interview with trained nurse; or 
hospitalization with or death due to ICD-10 code for sciatica (M54.3); or 
hospitalization with ICD-9 code for sciatica (7243) 
Osteoporosis 
Self-reported history of osteoporosis during verbal interview with trained nurse; 
or hospitalization with or death due to ICD-10 code for osteoporosis 
with/without pathological fracture (M80, M81); or hospitalization with ICD-9 
code for osteoporosis (7330) 
Osteoarthritis 
Self-reported history of osteoarthritis during verbal interview with trained nurse; 
or hospitalization with or death due to ICD-10 code for polyarthrosis, 
coxarthrosis, gonarthrosis, first carpometacarpal or other arthrosis (M15, M16, 
M17, M18, M19); or hospitalization with ICD-9 code for osteoarthrosis (715) 
Rheumatoid arthritis 
Self-reported history of rheumatoid arthritis during verbal interview with trained 
nurse; or hospitalization with or death due to ICD-10 code for rheumatoid 
arthritis (M05, M06); or hospitalization with ICD-9 code for rheumatoid arthritis 
(714) 
Lupus erythematosus 
Self-reported history of systemic lupus erythematosus during verbal interview 
with trained nurse; or hospitalization with or death due to ICD-10 code for 
lupus erythematosus (L93) or systemic lupus erythematosus (M32.1, M32.8, 
M32.9); or hospitalization with ICD-9 code for lupus erythematosus (6954) 
Sarcoidosis 
Self-reported history of sarcoidosis during verbal interview with trained nurse; 
or hospitalization with or death due to ICD-10 code for sarcoidosis (D86); or 
hospitalization with ICD-9 code for sarcoidosis (135) 
Psoriasis 
Self-reported history of psoriasis during verbal interview with trained nurse; or 
hospitalization with or death due to ICD-10 code for psoriasis (L40), psoriatic 
arthropathy, arthritis mutilans, psoriatic spondylitis (M07.0, M07.1, M07.2, 
M07.3); or hospitalization with ICD-9 code for psoriasis/psoriatic arthropathy 
(6960, 6961) 
Dermatitis 
Self-reported history of eczema/dermatitis during verbal interview with trained 
nurse; or hospitalization with or death due to ICD-10 code for atopic dermatitis, 
seborrhoeic dermatitis, diaper dermatitis, allergic contact dermatitis, 
irritant/unspecified contact dermatitis (L20, L21, L22, L23, L24, L25, L26, L27, 
L30), Lichen simplex chronicus and prurigo (L28), pruritus (L29); or 
hospitalization with ICD-9 code for atopic/contact dermatitis (691, 692) 
Iron deficiency anemia 
Self-reported history of iron deficiency anemia during verbal interview with 
trained nurse; or hospitalization with or death due to ICD-10 code for iron 
deficiency anemia (D50); or hospitalization with ICD-9 code for iron deficiency 
anemia (280) 
Asthma 
Self-reported history of asthma during verbal interview with trained nurse; or 
hospitalization with or death due to ICD-10 code for asthma or status 
asthmaticus (J45, J46); or hospitalization with ICD-9 code for asthma (493) 
Chronic obstructive 
pulmonary disease 
Self-reported history of chronic obstructive airways/emphysema during verbal 
interview with trained nurse; or hospitalization with or death due to ICD-10 
code for chronic bronchitis, emphysema, or other chronic obstructive 
pulmonary disease (J41, J42, J43, J44); or hospitalization with ICD-9 code for 
chronic bronchitis, emphysema or unspecified chronic airways obstruction 
(491, 492, 496) 
Pneumonia 
Self-reported history of pneumonia during verbal interview with trained nurse; 
or hospitalization with or death due to ICD-10 code for pneumonia (J12, J13, 
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J14, J15, J16, J17, J18); or hospitalization with ICD-9 code for pneumonia 
(481, 482, 483, 484, 485, 486) 
Allergic rhinitis 
Self-reported history of hayfever/allergic rhinitis during verbal interview with 
trained nurse; or hospitalization with or death due to ICD-10 code for allergic 
rhinitis (J30.1-J30.4); or hospitalization with ICD-9 code for allergic rhinitis 
(477) 
Sleep apnea 
Self-reported history of sleep apnea during verbal interview with trained nurse; 
or hospitalization with or death due to ICD-10 code for sleep apnea (G47.3) 
Cataract 
Self-reported history of cataract during verbal interview with trained nurse; or 
hospitalization with or death due to ICD-10 code for cataract (H25, H26); or 
hospitalization with ICD-9 code for cataract (366) 
Glaucoma 
Self-reported history of glaucoma during verbal interview with trained nurse; or 
hospitalization with or death due to ICD-10 code for glaucoma (H40); or 
hospitalization with ICD-9 code for glaucoma (365) 
Lung cancer 
Self-reported history of lung cancer during verbal interview with trained nurse; 
or hospitalization with or death due to ICD-10 code for malignant neoplasm of 
bronchus and lung (C34); or hospitalization with ICD-9 code for malignant 
neoplasm of bronchus and lung (1629) 
Breast cancer 
Self-reported history of breast cancer during verbal interview with trained 
nurse; or hospitalization with or death due to ICD-10 code for malignant 
neoplasm of breast (C50); or hospitalization with ICD-9 code for malignant 
neoplasm of breast (174) 
Colorectal cancer 
Self-reported history of colorectal/sigmoid/rectal cancer during verbal interview 
with trained nurse; or hospitalization with or death due to ICD-10 code for 
malignant neoplasm of colon (C18.0, C18.2-18.9); or hospitalization with ICD-
9 code for malignant neoplasm of colon/rectum (1532, 1533, 1541) 
Skin cancer 
Self-reported history of skin, malignant melanoma, non-melanoma skin cancer, 
or squamous cell carcinoma during verbal interview with trained nurse; or 
hospitalization with or death due to ICD-10 code for malignant melanoma or 
other malignant neoplasms of skin (C43, C44); or hospitalization with ICD-9 
code for malignant melanoma/neoplasm of skin (172, 173) 
Prostate cancer 
Self-reported history of prostate cancer during verbal interview with trained 
nurse; or hospitalization with or death due to ICD-10 code for malignant 
neoplasm of prostate (C61) 
Cervical cancer 
Self-reported history of cervical cancer during verbal interview with trained 
nurse; or hospitalization with or death due to ICD-10 code for malignant 
neoplasm of cervix uteri (C53) 
Bladder cancer 
Self-reported history of bladder cancer during verbal interview with trained 
nurse; or hospitalization with or death due to ICD-10 code for malignant 
neoplasm of bladder (C67); or hospitalization with ICD-9 code for malignant 
neoplasm of bladder (188) 
Gestational hypertension – 
preeclampsia 
Self-reported history of gestational hypertension/pre-eclampsia during verbal 
interview with trained nurse; or hospitalization with or death due to ICD-10 
code for pre-existing hypertensive disorder with superimposed proteinuria 
(O11), gestational hypertension (O13, O14), eclampsia (O15); or 
hospitalization with ICD-9 code for transient hypertension of pregnancy, 
preeclampsia or eclampsia (6423, 6424, 6425, 6426, 6427) 
 
Death 












BMI = body-mass index; ICD = International Classification of Disease; OPCS = Office of Population, 
Census and Surveys: Classification of Interventions and Procedures  
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Supplementary Table 14. Phenome-wide association results for rs5942634-T in the UK 
Biobank attaining at least nominal association (P < 0.05) 
 
Phenotype beta SE P 
Hypercholesterolemia -0.0602 5.20x10-03 5.88 x10-31 
BMI 0.0657 9.27x10-03 1.39 x10-12 
Percentage body fat 0.0674 0.0124 4.92 x10-08 
Glaucoma -0.0705 0.0149 2.25 x10-06 
Ever smoked 0.0177 3.95x10-03 7.45 x10-06 
Hypertension -0.0188 4.28x10-03 1.14 x10-05 
Diabetes mellitus, All -0.0306 7.72x10-03 7.42 x10-05 
Diabetes mellitus, type 2 -0.0346 8.91x10-03 1.02 x10-04 
Enlarged prostate -0.0340 9.41x10-03 3.04 x10-04 
Coronary artery disease -0.0256 8.52x10-03 2.63 x10-03 
Gout -0.0350 0.0129 6.52x10-03 
Sciatica 0.0319 0.0158 0.0431 
Intracerebral hemorrhage -0.0844 0.0420 0.0448 
 
Logistic regression association analyses were adjusted for age, sex, array type, and principal 
components. P-values presented are two-sided, and p-values < 6.3x10-4 were considered significant 
given multiple-hypothesis testing. 
BMI = body-mass index (kg/m2); se = standard error.  
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Supplementary Table 15. Phenome-wide association results for rs5942648-A in the UK 
Biobank attaining at least nominal association (P < 0.05) 
 
Phenotype beta se P 
Hypercholesterolemia -0.0612 5.20x10-03 5.57 x10-32 
BMI 0.0682 9.26x10-03 1.79 x10-13 
Percentage body fat 0.0717 0.0123 6.35 x10-09 
Glaucoma -0.0674 0.0149 6.05 x10-06 
Hypertension -0.0187 4.28x10-03 1.17 x10-05 
Ever smoked 0.0166 3.94x10-03 2.55 x10-05 
Diabetes mellitus, type 2 -0.0357 8.9x10-03 6.15 x10-05 
Diabetes mellitus, all -0.0308 7.71x10-03 6.55 x10-05 
Enlarged prostate -0.0334 9.4x10-03 3.79 x10-04 
Coronary artery disease -0.0276 8.51x10-03 1.18 x10-03 
Gout -0.0362 0.0129 4.89 x10-03 
Intracerebral hemorrhage -0.0896 0.0421 0.0331 
Irritable bowel syndrome -0.0244 0.0116 0.0353 
  
Logistic regression association analyses were adjusted for age, sex, array type, and principal 
components. P-values presented are two-sided, and p-values < 6.3x10-4 were considered significant 
given multiple-hypothesis testing. 
BMI = body-mass index (kg/m2); se = standard error.  
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Supplementary Table 16. Phenome-wide association results for rs5985504-T in the UK 
Biobank attaining at least nominal association (P < 0.05) 
 
Phenotypes beta se P 
Hypercholesterolemia -0.0581 5.19 x10-03 4.49 x10-29 
BMI 0.0742 9.25 x10-03 1.05 x10-15 
Percentage body fat 0.0819 0.0123 3.06 x10-11 
Glaucoma -0.0677 0.0149 5.19 x10-06 
Hypertension -0.0176 4.27 x10-03 3.91 x10-05 
Diabetes mellitus, type 2 -0.0358 8.89 x10-03 5.68 x10-05 
Ever smoked 0.0155 3.94 x10-03 8.49 x10-05 
Diabetes mellitus, all -0.0299 7.7 x10-03 1.05 x10-04 
Enlarged prostate -0.0364 9.39 x10-03 1.06 x10-04 
Coronary artery disease -0.0275 8.5 x10-03 1.20 x10-03 
Gout -0.0361 0.0128 4.98 x10-03 
Sciatica 0.0383 0.0157 0.0149 
Intracerebral hemorrhage -0.0974 0.0421 0.0206 
Irritable bowel syndrome -0.0232 0.0116 0.0450 
  
Logistic regression association analyses were adjusted for age, sex, array type, and principal 
components. P-values presented are two-sided, and p-values < 6.3x10-4 were considered significant 
given multiple-hypothesis testing. 
BMI = body-mass index (kg/m2); se = standard error.  
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Supplementary Table 17. Association of NMR lipoproteins with rs5942634, rs5985504, and 
rs5942648 in up to 6,356 FHS and MESA individuals. 
 
SNP Lipoprotein Beta SE P 
rs5942634 Very Large TRLP 0.003 0.014 0.805 
rs5942634 Large TRLP -0.014 0.016 0.366 
rs5942634 Medium TRLP -0.023 0.016 0.143 
rs5942634 Small TRLP -0.002 0.016 0.911 
rs5942634 Very Small TRLP -0.020 0.016 0.214 
rs5942634 Large LDLP 0.021 0.016 0.176 
rs5942634 Medium LDLP -0.007 0.016 0.664 
rs5942634 Small LDLP -0.031 0.016 0.049 
rs5942634 Large HDLP -0.004 0.016 0.794 
rs5942634 Medium HDLP 0.047 0.016 0.003 
rs5942634 Small HDLP -0.026 0.016 0.102 
rs5942634 TRL Size -0.008 0.016 0.629 
rs5942634 LDL Size 0.042 0.016 0.008 
rs5942634 HDL Size 0.015 0.016 0.345 
rs5942634 TRL Triglycerides -0.022 0.016 0.162 
rs5942634 TRL Cholesterol -0.015 0.016 0.351 
rs5942648 Very Large TRLP 0.000 0.014 0.992 
rs5942648 Large TRLP -0.017 0.016 0.285 
rs5942648 Medium TRLP -0.008 0.016 0.615 
rs5942648 Small TRLP 0.004 0.016 0.798 
rs5942648 Very Small TRLP -0.024 0.016 0.132 
rs5942648 Large LDLP 0.027 0.016 0.088 
rs5942648 Medium LDLP -0.005 0.016 0.751 
rs5942648 Small LDLP -0.026 0.016 0.103 
rs5942648 Large HDLP -0.006 0.016 0.715 
rs5942648 Medium HDLP 0.051 0.016 0.001 
rs5942648 Small HDLP -0.027 0.016 0.087 
rs5942648 TRL Size -0.016 0.016 0.317 
rs5942648 LDL Size 0.042 0.016 0.008 
rs5942648 HDL Size 0.014 0.016 0.380 
rs5942648 TRL Triglycerides -0.015 0.016 0.342 
rs5942648 TRL Cholesterol -0.011 0.016 0.496 
rs5985504 Very Large TRLP -0.007 0.014 0.624 
rs5985504 Large TRLP -0.020 0.016 0.193 
rs5985504 Medium TRLP -0.007 0.016 0.639 
rs5985504 Small TRLP 0.007 0.016 0.648 
rs5985504 Very Small TRLP -0.019 0.016 0.227 
rs5985504 Large LDLP 0.021 0.016 0.191 
rs5985504 Medium LDLP -0.004 0.016 0.819 
rs5985504 Small LDLP -0.022 0.016 0.159 
rs5985504 Large HDLP -0.010 0.016 0.543 
rs5985504 Medium HDLP 0.043 0.016 0.007 
rs5985504 Small HDLP -0.023 0.016 0.156 
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rs5985504 TRL Size -0.023 0.016 0.144 
rs5985504 LDL Size 0.034 0.016 0.031 
rs5985504 HDL Size 0.008 0.016 0.624 
rs5985504 TRL Triglycerides -0.019 0.016 0.236 
rs5985504 TRL Cholesterol -0.018 0.016 0.254 
 
Linear regression association analyses were adjusted for age, sex, and lipid-lowering therapy. P-
values presented are two-sided and p-values < 0.001 are considered significant accounting for 
multiple-hypothesis testing.  
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Supplementary Table 18. Association of rs5942634-T with body composition measures in the 
UK Biobank. 
 
Location Beta (kg) SE P 
Whole body 0.118 0.018 4.8 x10-11 
Leg, right 0.021 2.9 x10-03 3.6 x10-12 
Leg, left 0.020 3.0 x10-03 3.4 x10-12 
Arm, right 6.8 x10-03 1.2 x10-03 4.1 x10-09 
Arm, left 7.6 x10-03 1.3 x10-03 1.7 x10-09 
Trunk 0.063 0.010 4.0 x10-10 
 
Linear regression association analyses were adjusted for age, sex, array type, and principal 
components. P-values presented are two-sided, and p-values < 5.6x10-3 were considered significant 
given multiple-hypothesis testing. 
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Supplementary Table 19. Association of lipid-associated chrXq23 variants with visual acuity in 
the UK Biobank 
 
Variant Beta SE P 
rs5942634-A -1.84x10-4 5.33x10-4 0.73 
rs5942648-T -8.29x10-5 5.28x10-4 0.88 
rs5985504-T -1.04x10-4 5.30x10-4 0.84 
 
The effect estimates are represented in “logMAR” units, where, for example, 0 represents 20/20 
vision and 1 represents 20/200 vision. Negative values represent vision better than 20/20 (e.g., -0.1 
represents 20/16 vision). Linear regression association analyses were adjusted for age, sex, array 
type, and principal components. P-values presented are two-sided, and further adjustment was not 
performed for this secondary analysis. 
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Supplemental Table 20. Association between rs5942634 and gene expression of genes in 








Allele Beta SE P 
Muscle Skeletal ENSG00000101938.10 CHRDL1 T A -0.166 0.024 1.19x10-11 
Adipose 
Subcutaneous ENSG00000101938.10 CHRDL1 T A -0.160 0.029 8.64x10-8 
Adipose Visceral 
Omentum ENSG00000101938.10 CHRDL1 T A -0.169 0.036 4.33x10-6 
Muscle Skeletal ENSG00000243978.4 RTL9 T A 0.175 0.041 2.66x10-5 
Liver ENSG00000101938.10 CHRDL1 T A -0.254 0.061 5.93x10-5 
Small Intestine 
Terminal Ileum ENSG00000101938.10 CHRDL1 T A -0.107 0.049 0.030 
Adipose Visceral 
Omentum ENSG00000243978.4 RTL9 T A 0.098 0.054 0.070 
Muscle Skeletal ENSG00000077264.10 PAK3 T A -0.040 0.034 0.242 
Liver ENSG00000243978.4 RTL9 T A 0.070 0.068 0.305 
Adipose Visceral 
Omentum ENSG00000101935.5 AMMECR1 T A 0.027 0.027 0.313 
Small Intestine 
Terminal Ileum ENSG00000068366.15 ACSL4 T A -0.037 0.037 0.320 
Adipose 
Subcutaneous ENSG00000077264.10 PAK3 T A -0.024 0.025 0.341 
Small Intestine 
Terminal Ileum ENSG00000077264.10 PAK3 T A 0.053 0.056 0.353 
Muscle Skeletal ENSG00000157600.7 TMEM164 T A 0.030 0.035 0.391 
Muscle Skeletal ENSG00000077274.7 CAPN6 T A 0.019 0.024 0.416 
Adipose 
Subcutaneous ENSG00000101935.5 AMMECR1 T A 0.024 0.034 0.479 
Muscle Skeletal ENSG00000068366.15 ACSL4 T A -0.015 0.022 0.489 
Liver ENSG00000101935.5 AMMECR1 T A 0.030 0.060 0.621 
Small Intestine 
Terminal Ileum ENSG00000157600.7 TMEM164 T A 0.012 0.025 0.624 
Adipose 
Subcutaneous ENSG00000077274.7 CAPN6 T A 0.017 0.034 0.624 
Liver ENSG00000077264.10 PAK3 T A 0.038 0.078 0.628 
Whole Blood ENSG00000068366.15 ACSL4 T A -0.006 0.012 0.644 
Whole Blood ENSG00000101935.5 AMMECR1 T A 0.014 0.033 0.673 
Adipose 
Subcutaneous ENSG00000243978.4 RTL9 T A -0.016 0.039 0.682 
Adipose Visceral 
Omentum ENSG00000157600.7 TMEM164 T A 0.010 0.025 0.695 
Small Intestine 
Terminal Ileum ENSG00000077274.7 CAPN6 T A 0.024 0.062 0.705 
Whole Blood ENSG00000101938.10 CHRDL1 T A -0.015 0.040 0.712 
Adipose 
Subcutaneous ENSG00000157600.7 TMEM164 T A -0.009 0.024 0.728 
Adipose Visceral 
Omentum ENSG00000077274.7 CAPN6 T A -0.010 0.032 0.756 
Adipose 
Subcutaneous ENSG00000077279.12 DCX T A 0.010 0.035 0.785 
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Liver ENSG00000068366.15 ACSL4 T A -0.018 0.071 0.797 
Adipose Visceral 
Omentum ENSG00000068366.15 ACSL4 T A 0.005 0.024 0.852 
Whole Blood ENSG00000157600.7 TMEM164 T A -0.005 0.025 0.853 
Small Intestine 
Terminal Ileum ENSG00000101935.5 AMMECR1 T A -0.010 0.055 0.861 
Liver ENSG00000077274.7 CAPN6 T A 0.011 0.072 0.878 
Muscle Skeletal ENSG00000101935.5 AMMECR1 T A -0.005 0.036 0.885 
Adipose Visceral 
Omentum ENSG00000077264.10 PAK3 T A 0.005 0.036 0.885 
Liver ENSG00000157600.7 TMEM164 T A 0.007 0.054 0.893 
Adipose 
Subcutaneous ENSG00000068366.15 ACSL4 T A 0.002 0.025 0.928 
 
Queries of lipid-associated alleles with gene expression from linear regression in the GTEx dataset 
are depicted. No further adjustment of effects or two-sided p-values were performed.  
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Supplemental Table 21. Colocalization of lipid with gene expression near index association 







estimate SE Z P 
ACSL4 Adipose_Subcutaneous 264 0.084 0.032 2.613 0.009 
ACSL4 Adipose_Visceral_Omentum 264 -0.021 0.029 -0.699 0.484 
ACSL4 Liver 262 -0.059 0.022 -2.606 0.009 
ACSL4 Muscle_Skeletal 264 0.035 0.020 1.766 0.077 
ACSL4 Small_Intestine_Terminal_Ileum 260 0.147 0.024 6.057 1.39x10-9 
ACSL4 Whole_Blood 264 0.058 0.033 1.761 0.078 
AMMECR1 Adipose_Subcutaneous 493 0.055 0.030 1.800 0.072 
AMMECR1 Adipose_Visceral_Omentum 493 -0.060 0.026 -2.297 0.022 
AMMECR1 Liver 475 -0.047 0.028 -1.685 0.092 
AMMECR1 Muscle_Skeletal 493 0.019 0.024 0.766 0.444 
AMMECR1 Small_Intestine_Terminal_Ileum 479 -0.024 0.033 -0.732 0.464 
AMMECR1 Whole_Blood 493 0.046 0.031 1.498 0.134 
CAPN6 Adipose_Subcutaneous 318 0.018 0.021 0.876 0.381 
CAPN6 Adipose_Visceral_Omentum 318 0.016 0.022 0.723 0.470 
CAPN6 Liver 315 -0.006 0.018 -0.346 0.729 
CAPN6 Muscle_Skeletal 318 0.018 0.023 0.794 0.427 
CAPN6 Small_Intestine_Terminal_Ileum 314 -0.010 0.016 -0.625 0.532 
CHRDL1 Adipose_Subcutaneous 674 1.104 0.011 98.007 1.35x10-2088 
CHRDL1 Adipose_Visceral_Omentum 674 1.295 0.028 45.956 4.31x10-461 
CHRDL1 Liver 658 1.439 0.019 76.238 8.12x10-1265 
CHRDL1 Muscle_Skeletal 674 0.933 0.013 70.439 4.41x10-1080 
CHRDL1 Small_Intestine_Terminal_Ileum 599 1.789 0.046 38.952 6.96x10-332 
CHRDL1 Whole_Blood 674 0.718 0.129 5.590 2.27x10-8 
DCX Adipose_Subcutaneous 252 0.085 0.034 2.535 0.011 
PAK3 Adipose_Subcutaneous 762 -0.062 0.021 -2.913 0.004 
PAK3 Adipose_Visceral_Omentum 762 0.072 0.012 6.131 8.73x10-10 
PAK3 Liver 753 -0.071 0.016 -4.356 1.32x10-5 
PAK3 Muscle_Skeletal 762 0.035 0.015 2.253 0.024 
PAK3 Small_Intestine_Terminal_Ileum 753 -0.022 0.016 -1.366 0.172 
RTL9 Adipose_Subcutaneous 332 -0.020 0.034 -0.602 0.547 
RTL9 Adipose_Visceral_Omentum 332 -0.057 0.036 -1.579 0.114 
RTL9 Liver 324 -0.004 0.038 -0.107 0.915 
RTL9 Muscle_Skeletal 332 -0.147 0.036 -4.129 3.64x10-5 
TMEM164 Adipose_Subcutaneous 465 -0.174 0.021 -8.222 2.01x10-16 
TMEM164 Adipose_Visceral_Omentum 465 -0.185 0.023 -8.040 8.99x10-16 
TMEM164 Liver 452 0.004 0.020 0.184 0.854 
TMEM164 Muscle_Skeletal 465 0.099 0.029 3.459 0.001 
TMEM164 Small_Intestine_Terminal_Ileum 459 -0.114 0.033 -3.485 4.93x10-4 
TMEM164 Whole_Blood 465 0.015 0.003 4.652 3.28x10-6 
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Lipid effects were adjusted for age, age2, sex, batch, and principal components of ancestry, as well 
as site-specific covariates where appropriate using linear regression. Gene expression effects were 
obtained directly from GTEx. Two-sided p-values < 0.001 were considered significant accounting for 
multiple-hypothesis testing.  
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Supplemental Table 22. Top gene-based association results on the X chromosome in TOPMed 
with p < 0.001. 
 






TG TIMP1 HC LOF + metaSVM 26 234 196 0.00019 
TG HDX HC LOF + metaSVM 9 11 10 0.00066 
TG SLC6A14 HC LOF 6 8 7 0.00067 
TG DMD HC LOF + metaSVM 113 669 544 0.00100 
 
Rare variant SKAT association tests were adjusted for age, age2, sex, batch, and principal 
components, as well as site-specific covariates where appropriate. Two-sided p-values < 6.7x10-5 
were considered significant given multiple-hypothesis testing. 









Flow chart of the overall study, including cohorts and outcomes, is shown.  
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Supplementary Figure 2. Principal component plots of TOPMed participants. 
 
 
Principal components of ancestry of TOPMed participants are depicted colored by self-identified race. 
AI_AN = American Indian / Native American / Alaskan Native; PC = principal components  
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(A) HDL cholesterol, (B) LDL cholesterol, (C) total cholesterol, and (D) triglycerides. Triglycerides are 
displayed on a log10 scale. Sample sizes for each cohort are listed in Supplementary Table 4. For the 
boxplots, the center diamond is the mean, center line is the median, top box bound is the third 
quartile, top whisker end is the third quartile plus 1.5 times the interquartile range, bottom box bound 
is the first quartile, and bottom whisker end is the first quartile minus 1.5 times the interquartile range. 
HDL = high-density lipoprotein; LDL = low-density lipoprotein.  
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(A) HDL cholesterol, (B) LDL cholesterol, (C) total cholesterol, and (D) triglycerides. Sample sizes for 
each cohort are listed in Supplementary Table 4. For the boxplots, the center diamond is the mean, 
center line is the median, top box bound is the third quartile, top whisker end is the third quartile plus 
1.5 times the interquartile range, bottom box bound is the first quartile, and bottom whisker end is the 
first quartile minus 1.5 times the interquartile range. 
HDL = high-density lipoprotein; LDL = low-density lipoprotein.  
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Supplementary Figure 5. Quantile-quantile plots of chromosome X genetic variants’ 




(A) HDL cholesterol (=1.11), (B) LDL cholesterol (=1.13), (C) total cholesterol (=1.17), and (D) 
triglycerides (=1.09).  
HDL = high-density lipoprotein; LDL = low-density lipoprotein. 
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Supplementary Figure 6. Manhattan plots of chromosome X genetic variants’ associations 




(A) HDL cholesterol, (B) LDL cholesterol, (C) total cholesterol, and (D) triglycerides.  
HDL = high-density lipoprotein; LDL = low-density lipoprotein. 
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Supplementary Figure 7. LocusZoom plots for associated variants at chrXq23 with total 
cholesterol in TOPMed. 
 
 
Regional association plot at chromosome Xq23 in TOPMed for the association of total cholesterol. 
Lead lipid-associated variants in Table 1 are indicated.  
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Supplementary Figure 8. ChrXq23 variants associated with total cholesterol and predicted 
liver enhancer regions. 
  
 
Yellow regions are predicted adult liver enhancers. Green vertical lines represent chrXq23 variants 
associated with total cholesterol with two-sided P < 1x10-13 (N = 119 variants) after adjustment for 
age, age2, sex, batch, and principal components of ancestry, as well as site-specific covariates where 
appropriate using linear regression. In this model, accounting for multiple-hypothesis testing, p-values 




Supplementary Figure 9. Proposed enhancer contacts combining reference Hi-C, ChIA-PET, 




Contacts to rs5942634 (central contacts) are depicted using virtual 4C data 
(http://promoter.bx.psu.edu/hi-c/virtual4c.php) using K562 cell line data.42 A contact upstream of 
CHRDL1 is depicted.  
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Effects of ChrXq23 variants on total cholesterol (TC) vs effects of these variants on coronary artery 

















































































































































































Supplementary Figure 11. Correlation between total cholesterol and gene expression variant 
effects at chrXq23. 
 
 
Correlation of Z-scores (beta/standard error) between total cholesterol ~ variant and gene expression 
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